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ABSTRACT 
 
Nature has proven to be an endless source of abundant diversity of chemical entities with 
varying biological activities. The World Health Organization (WHO) estimates that 80% of the 
world's population depends on traditional medicine for treating their everyday health problems. 
According to Gordon Cragg, former director of the natural products branch of the NCI, ″Nature 
has produced wonderfully complex molecules that no synthetic chemist could ever dream up.″ 
Moreover, he emphasized that over 60% of cancer therapeutics have been derived from nature 
whether directly through isolation or indirectly through semi-synthesis. Various examples have 
been reported such as extracts from Catharanthus roseus (Rosy Periwinkle) used for treatment of 
Hodgkin's disease and leukemia, digitalis from Digitalis purpurea (foxglove) for treatment of 
heart disease, galantamine from Galanthus caucasicus (snowdrops) for treatment of Alzheimer's 
disease, and paclitaxel from the bark of the Pacific yew tree to treat cancer. 
During the course of these studies, we researched the potential of natural products to 
provide drugs for treatment of human and plant diseases for which no adequate therapy exists. 
For instance, methicillin-resistant Staphylococcus aureus (MRSA) is a destructive pathogen with 
a high patient mortality rate. Over 50% of the Staph. aureus infections around the world are 
caused by MRSA. In the first chapter, we will address the bioassay-guided isolation and 
characterization of a series of anti-MRSA active glycosides that exhibit a high degree of 
selectivity for MRSA from the leaves of the common American sycamore, Platanus occidentalis. 
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The isolated metabolites; E,E-platanoside [kaempferol 3-O-α-L-(2'',3''-di-E-p-
coumaroyl)rhamnoside, IC50 2.0 µg/mL], E,Z-platanoside [kaempferol 3-O-α-L-(2''-E-p-
coumaroyl-3''-Z-p-coumaroyl)rhamnoside, IC50 0.8 µg/mL], Z,E-platanoside [kaempferol 3-O-α-
L-(2''-Z-p-coumaroyl-3''-E-p-coumaroyl)rhamnoside, IC50 0.7 µg/mL], and Z,Z-platanoside 
[kaempferol 3-O-α-L-(2'',3''-di-Z-p-coumaroyl)rhamnoside, IC50 0.4 µg/mL] have been shown to 
prevent growth of MRSA on surfaces and systemically.  
The in vitro anti-MRSA activity of these metabolites indicated that changing the 
configuration of the double bond in the p-comaroyl units greatly affects the MRSA activity. This, 
in turn, encouraged us to establish economic methods to transform the less active E,E-
platanoside to the more active Z, Z-platanoside. Light-mediated isomerization in platanosides 
provides a precise, noninvasive, and “green” approach for controlling MRSA activity. In the 
second chapter, the development of a simple “green” chemistry approach is described that uses 
light induced photoisomerization for transforming the thermodynamically stable E,E-platanoside 
to the Z,E-, E,Z- and Z,Z-platanosides. This provided support for the light mediated 
photoisomerization over the enzymatic control theory for the biosynthesis formation of the Z-
isomers. 
American sycamore is significant to the forest products industry due to its use as pulp-
wood for making paper and fiberboard, and sawlogs for manufacturing butcher's blocks, 
furniture, interior trim, boxes, and flooring. Historically, American sycamore has held, and 
continues to hold, good potential as a dedicated biofuels crop grown on short rotations in 
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plantations. However, the growth and productivity of sycamore plantations is hampered by 
bacterial leaf scorch disease (BLS) caused by Xylella fastidiosa. Strains of this bacterium are the 
major cause of various plant diseases such as phony peach disease (PPD), plum leaf scald (PLS), 
and Pierce's disease (PD) of grapes, citrus variegated chlorosis (CVC), and leaf scorch of 
almond, oleander, and pear. The isolated anti-MRSA metabolites are found in greater 
concentrations in healthy sycamore trees versus diseased trees suggesting an ecological link 
between tree health and glycoside content. The third chapter describes this ecological link and 
presents data that demonstrates the ability of the metabolites to inhibit X. fastidiosa at nanomolar 
concentrations (MIC ≤ 17-67 nM). The presence of these metabolites in sycamore has the 
potential to be a useful analytical tool for selecting disease-resistant strains. 
 Depression is the most common disease of the central nervous system affecting 
approximately 17% of Americans each year. According to the National Institute of Mental 
Health (NIMH), every year about 40 million American adults suffer from anxiety disorders that 
frequently co-occur with other psychiatric illnesses like depression. Recently, our group reported 
the isolation of several marine indole alkaloids and evaluated their biological activity in the 
forced swim (FST) and locomotor activity tests, revealing their potential to become new 
antidepressant drug leads.
 
Among the isolated compounds, 5-bromo-N,N-dimethyltryptamine  
was found to display a high sedative effect in the locomotor activity test. Owing to the limited 
amounts of this compound obtained from isolation, a synthetic approach was adopted to prepare 
5-bromo-N,N-dimethyltryptamine and its derivatives to study the structure activity relationships 
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(SAR) and complete the dose-response experiments. In the fourth chapter, the synthesis is 
described of a series of 2-(5-halo-1H-indol-3-yl)-N,N-dimethylethanamines, as is the evaluation 
of their in vivo  antidepressant and sedative activities using the FST and locomotor activity tests. 
Of the synthetically prepared compounds, 2-(1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide, 2-
(5-chloro-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamide, 2-(1H-indol-3-yl)-N,N-
dimethylethanamine, 2-(5-chloro-1H-indol-3-yl)-N,N-dimethylethanamine, and 2-(5-iodo-1H-
indol-3-yl)-N,N-dimethylethanamine have been shown to possess antidepressant-like action. 
Dose response studies were completed for the active compounds. 
Manzamine A is an alkaloid that contains a unique multi-heterocyclic ring system 
coupled to a β-carboline moiety. Manzamine A showed potent in vitro antimalarial activity 
against P. falciparum D6 and W2 (0.017-0.020 µM), but its toxicity hindered its development as 
a drug lead. Malaria, a major tropical infectious disease caused primarily by the protozoan 
parasite Plasmodium falciparum, is responsible for the death of more than 1.12 million 
individuals every year. Recently, Ihara reported that the π-delocalized lipophilic cationic (DLC) 
structures of various β-carboline natural products, display reasonable antimalarial activity against 
P. falciparum with low cytotoxicity against mammalian cells. The fifth chapter describes the 
synthesis of mono- and di-methylated quaternary carbolinium cations of manzamine A and 
evaluations of their in vitro antimalarial and antimicrobial activities, cytotoxicity, and also their 
potential for glycogen synthase kinase (GSK-3β) inhibition using molecular docking studies. 
Among the analogs, 2-N-methylmanzamine A exhibited antimalarial activity (IC50 0.7 – 1.0 
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µM), but was less potent than manzamine A. However, the compound was significantly less 
cytotoxic to mammalian kidney fibroblasts with a selectivity index in the same range as 
manzamine A. 
 One of the most serious threats to humans is hepatitis C virus (HCV) infections affecting 
approximately 4 million individuals in the United States, and 200-300 million individuals 
worldwide, causing over 8,000 deaths each year.
 
 HCV can progress to severe liver disorders 
such as fibrosis, cirrhosis, and hepatocellular carcinoma. A rare Latin American plant extract 
provided through collaboration with the National Cancer Institute (NCI) repository (No. 77951) 
showed potent anti-HCV activity.  
 Diplostephium rhododendroides (family Asteraceae) is only found between Ecuador and 
Colombia and has not been subjected to phytochemical screening. The last chapter describes the 
isolation and identification from this rare plant of anti-HCV oleanane-triterpenes complex 
glycosides with m/z of 1700-1800. The isolated rhododendrosaponins I-III have shown 
exceptional activity (EC50 0.2 µg/mL) against HCV and warrant further evaluations. 
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CHAPTER I 
 
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS ACTIVE METABOLITES 
FROM PLATANUS OCCIDENTALIS (AMERICAN SYCAMORE) 
Published in J. Nat. Prod. 2009, 72, 2141–2144. 
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 2 
Methicillin-resistant Staphylococcus aureus (MRSA) is a serious pathogen with 
significant patient mortality.
1,2 
Currently, over 50% of the Staph. aureus infections around the 
world are caused by MRSA.
3,4
 Hospital-acquired infections of MRSA (HA-MRSA) have been 
shown to be resistant to multiple antibiotics. However, MRSA has recently developed into a 
community-associated pathogen (CA-MRSA) infecting individuals that have not been 
hospitalized within a year. CA-MRSA causes skin infections with abscess formation and 
cellulitis and is currently sensitive to some antibiotics.
5
  
The glycopeptide antibiotic vancomycin has been used as a drug of choice for MRSA 
infections. With a reported success rate of 35-57%, its side effects, including nosocomial 
pneumonia, hearing loss in the young and old, skin and soft tissue infections, and low bone 
penetration, limit vancomycin’s utility. Moreover, the increased use of vancomycin, especially in 
chronic conditions, has resulted in the emergence of MRSA with reduced susceptibility to 
glycopeptides.
6-8
  
The most effective anti-MRSA drug used currently is daptomycin, a cyclic lipopeptide 
derived from the fermentation of Streptomyces roseosporus. Daptomycin is most useful for short 
durations and for the treatment of persistent MRSA infections unaffected by other drug 
treatments such as vancomycin. Its mechanism of action involves binding to the bacterial cell 
membrane, causing depolarization of the membrane potential leading to inhibition of protein, 
DNA, and RNA synthesis. However, various side effects were reported for daptomycin, 
including an increase in blood creatine phosphokinase, rhabdomyolysis, skin exfoliation, and 
skin ulcers.  
 3 
  The American sycamore [Platanus occidentalis L. (family Platanaceae)] is a large, fast-
growing tree with maximum growth up to 50 m in height and 3.2 m in diameter; it is widely 
distributed in the eastern United States where it grows on a variety of soils and sites and is often 
found near lakes and streams.
9,10
 Its safe use by humans is known from its use in traditional folk 
medicine for the treatment of a wide variety of conditions. The species has been used frequently 
for its antimicrobial and antiseptic properties. Native Americans used P. occidentalis as a cold 
and cough remedy, as well as a dietary supplement like tea, dermatological, gynecological, 
respiratory, and gastrointestinal aid.
11 
The bark was used with honey locust to relieve hoarseness 
and sore throats as well as to treat skin eruptions, scabs and eczema, lung problems, hemorrhage, 
and tuberculosis. A mixture of the bark, stems, and twigs was used to treat open wounds.  In 
addition, the bark has been used to treat colds, to purify the blood, for weight gain, and as an 
analgesic.
12
 The American sycamore was also generally taken as a cathartic, emetic, and 
antidiarrheal drug to treat dysentery.
13
 Previous chemical investigations of American sycamore 
have shown the presence of triterpenoids. This species produces betulinic aldehyde, betulinic 
acid, platanic acid, β-sitosterol, tiliroside,14 as well as kaempferol 3-O-rhamnosides.15 
Because of the increasing presence of MRSA-related infections and the emerging need 
for effective antibiotic therapies, bioassay-guided extraction of P. occidentalis was performed in 
order to identify new antibacterial compounds. All isolated metabolites were assayed in vitro for 
antifungal and antibacterial activity, and E,E-platanoside 1 was evaluated against MRSA in vivo. 
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                                              Figure 1. The structures of American sycamore glycosides 1-4 
 
Results and Discussion 
The antimicrobial evaluation of extracts from various parts of P. occidentalis showed the 
leaf extract to be highly active against MRSA (Table 1).   
 
 
 
 
 
 5 
Table 1. Antimicrobial activity of various parts of Platanus occidentalis  
Sample 
Code 
C. 
albicans
1
 
C. 
neoformans
2
 
A. 
fumigatus
3
 
 
MRSA
4
 
E. 
coli
5
 
P. 
aeruginosa
6
 
M. 
intracellulare
7
 
SMBB 7 19 2 33 22 4 0 
SL 6 4 6 55 27 24 0 
SBBB 5 12 4 9 15 0 0 
ST 6 25 5 30 17 15 0 
  1
Candida albicans, 
2
Candida neoformans, 
3
Aspergillus fumigatus, 
4
Methicillin resistant Staphylococcus 
aureus, 
5
Escherichia coli, 
6
Pseudomonas aeruginosa, 
7
Mycobacterium intracellulare; Concentration= 50 µg/mL; 
Samples showing % Growth Inhibition; < 50 are considered inactive. SMBB: sycamore middle branches bark, 
SL: sycamore leaves, SBBB: sycamore big branches bark, ST: sycamore twigs  
 
 
Four active metabolites, 1-4; (Figure 2) were shown by (+)-HRESIMS to possess the 
same mass with m/z 747.1647-747.1679, for the sodium-charged C39H32O14Na. The isolated 
compounds were shown to be L-rhamnose glycosides with different configurations of the p-
coumaroyl functionalities. Structural assignments of the new glycosides (2-4) were confirmed by 
examination of 
1
H and 
13
C NMR data and comparison with literature data (Tables 2 and 3).
16
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      Table 2.  
13
C NMR data of glycosides (1-4)
a
 
carbon 1 2 3 4 
2 157.9 157.7 157.6 157.5 
3 134.2 134.0 134.1 133.7 
4 178.1 177.9 177.9 177.5 
5 162.0 161.8 161.8 161.6 
6 98.7 98.6 98.6 99.9 
7 164.7 164.8 164.5 165.3 
8 93.6 93.4 93.5 94.4 
9 157.3 157.1 157.1 157.1 
10 104.7 104.4 104.6 103.3 
1’ 121.2 121.0 121.2 121.1 
2' 6' 130.7 130.5 130.5 130.4 
3', 5' 115.6 115.4 115.4 115.4 
4' 160.5 160.3 160.2 160.4 
1'' 99.1 98.8 98.9 98.9 
2'' 69.7 69.4 69.3 69.1 
3'' 71.9 71.4 71.7 71.5 
4'' 69.8 69.5 69.5 69.3 
5'' 71.0 70.9 70.8 70.8 
6'' 16.6 16.3 16.3 16.3 
1''', 1'''' 166.6, 167.3 166.4, 166.1 167.3, 165.2 166.1, 166.2 
2''', 2'''' 113.1, 113.7 112.9, 114.8 113.5, 114.1 114.0, 114.8 
3''', 3'''' 145.8, 146.5 146.2, 144.3 145.6, 145.2 144.4, 144.8 
4''', 4'''' 125.8, 125.9 125.7, 126.2 125.7, 126.0 126.0, 126.1 
5''', 9''', 5'''', 9'''' 130.0, 130.2 130.0, 132.4 129.8, 132.4 132.5, 132.5 
6''', 8''', 6'''', 8'''' 115.6, 115.7 114.5, 115.4 114.6, 115.5 114.5, 114.6 
7''', 7'''' 160.1, 160.3 160.0, 158.7 159.8, 158.7 158.8, 158.9 
         
a
Measured at 100 MHz for 
13
C in methanol-d4 
   
 7 
     Table 3. 1H NMR data of glycosides (1-4)a 
Proton 1 2 3 4 
6 6.11, s 6.26, s 6.22, s 6.13, S 
8 6.31, s 6.39, brs 6.41, brs 6.30, brs 
2', 6' 7.77, d (8.4) 7.87, d (8.4) 7.86, d (8.8) 7.83, d (8.4) 
3', 5' 6.89, d (8.8) 7.01, d (8.4) 6.98, d (8.8) 6.96, d (8.4) 
1'' 5.51, s 5.56, s 5.54, s 5.52, S 
2'' 5.73, bs 5.78, brs 5.78, brs 5.79, brs 
3'' 5.21, dd (9.6, 3.2) 5.27, dd (9.6, 3.2) 5.27, dd (9.2, 3.2) 5.21, dd (9.2, 3.2) 
4'' 3.55, t, (9.6) 3.58, t (9.6) 3.49, t (9.2) 3.48, t (9.6) 
5'' 3.45, m 3.52, m 3.53, m 3.52, m 
6'' 0.96, d (6.0) 1.04, d (6.0) 1.00, d (6.0) 0.97, d (5.6) 
2''', 2'''' 
6.29, d (15.6), 
6.21, d (15.6) 
6.31, d (16.0), 
5.72, d (12.8) 
6.30, d (16.0), 
5.81, d (12.8) 
5.72, d (12.8),   
5.74, d (12.8) 
3''', 3'''' 
7.50, d (15.6), 
7.52, d (15.6) 
7.59, d (16.0), 
6.88, d (12.8) 
7.61, d (16.0), 
6.94, d (12.8) 
6.89, d (12.8),   
6.86, d (12.8) 
5''', 9''' 
5'''', 9'''' 
7.28, d (8.8),  
7.36, d (8.4) 
7.47, d (8.4),  
7.71, d (8.4) 
7.36, d (8.8),  
7.64, d (8.8) 
7.71, d (8.4),     
7.62, d (8.4) 
6''', 8''', 
6'''', 8'''' 
6.65, d (8.4),   
6.70, d (8.4) 
6.81, m,          
6.81, m 
6.63, d (8.8),  
6.78, d (8.8) 
6.81, d (8.4),     
6.69, d (8.4) 
            a
Measured at 400 MHz for 
1
H in methanol-d4. “s” singlet, “brs” broad singlet, “d “ 
doublet, “dd” doublet of doublet,“t” triplet, “m” multiplet 
 
The
 1
H NMR spectra of compounds 1-4 clearly displayed the characteristic signals of the 
kaempferol nucleus as well as the anomeric α-configured sugar. The major glycoside isolated 
was E,E-platanoside (1) known as platanoside.
17
 In addition, three new anti-MRSA active 
metabolites were isolated in smaller amounts, E,Z-platanoside (2), Z,E-platanoside (3), and Z,Z-
platanoside (4). The isolated compounds exhibited similar UV spectra [λmax (MeOH) 268, 313 
nm]. The 
1
H and 
13
C NMR spectra of compounds 2-4 also resembled those of E,E-platanoside 1.  
 8 
Investigation of HMBC and COSY correlations indicated the positions of attachments of 
both p-coumaroyl units to L-rhamnose while 
1
H NMR coupling constants and NOESY spectra 
revealed the configurations at C-2''', C-3''' and C-2'''', C-3'''' for the isolated metabolites 2-4. 
HMBC correlations between H-2'' (5.81 Hz) and C-1''' (166.6 Hz) as well as between H-3'' (5.27 
Hz) and C-1''' (167.3 Hz) and the presence of the COSY correlation between H-2'' (5.81 Hz) and 
H-3'' (5.27 Hz) confirmed the attachment of the p-coumaroyl units to C-2'' and C-3''. The large 
coupling constant between H-2''' and H-3''' (15.6 Hz) in the known compound 1 indicated the 
trans relationship of the p-coumaroyl units at C-2'' and C-3'' of L-rhamnosyl moiety. For 
glycoside 2, HMBC correlations between H-2'' (5.78 Hz) and C-1''' (166.4 Hz) as well as 
between H-3'' (5.27 Hz) and C-1'''' (166.1 Hz) and the presence of the COSY correlation between 
H-2'' (5.78 Hz) and H-3'' (5.27 Hz), confirmed the attachment of the p-coumaroyl units to C-2'' 
and C-3''. The J value of H-2''' and H-3''' (16.0 Hz) of the p-coumaroyl functionality at C-2'' of 
the L-rhamnose indicated an E configuration, while the J value of H-2''''and H-3'''' (12.8 Hz) of 
the p-coumaroyl at C-3'' of the L-rhamnose indicated a Z configuration, which was also 
confirmed by the NOESY correlation between H-2''''and H-3''''. The opposite arrangement was 
shown for glycoside 3, where HMBC correlations between H-2'' (5.78 Hz) and C-1'''' (165.2 Hz) 
as well as between H-3'' (5.27 Hz) and C-1''' (167.3 Hz) and the presence of the COSY 
correlation between H-2'' (5.78 Hz) and H-3'' (5.27 Hz) confirmed the attachment of the p-
coumaroyl units at C-2'' and C-3''.  The J value of H-2''' and H-3''' (16.0 Hz) of the p-coumaroyl 
functionality at C-3'' of L-rhamnose supported the E configuration while the J value of H-2''''and 
H-3'''' (12.8 Hz) of the p-coumaroyl functionality at C-2'' of L-rhamnose suggested a Z 
configuration which was also confirmed by the NOESY correlation between H-2'''' and H-3''''. 
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HMBC correlations in glycoside 4 between H-2'' (5.79 Hz), C-1'''' (166.1 Hz) as well as H-3'' 
(5.21 Hz), C-1'''' (166.2 Hz) and the presence of the COSY correlation between H-2'' (5.79 Hz), 
H-3'' (5.21 Hz) confirmed the attachment of the p-coumaroyl units to C-2'' and C-3''. The small 
coupling constants (12.8 Hz) between H-2''''and H-3'''' established the Z configuration
18
 of the p-
coumaroyl groups at C-2'' and C-3'' of L-rhamnose; this was also confirmed by the NOESY 
correlations between H-2'''' and H-3''''. The platanosides were hydrolyzed and the absolute 
configuration of the sugar was shown to be L-rhamnose by GC comparison of its acetylated 
thiazolidine derivative with that of an L-rhamnose standard. The LC/MS analysis of the crude 
extract showed the presence of all four metabolites (1-4), which confirmed that no significant 
transformation of one isomer to the others occurred during the isolation and purification process 
(Figure 2).  
The LC/MS stability tests in various solvents revealed that water facilitated isomerization 
of the thermodynamically less stable isomers 3 and 4 to the most stable 1 in comparison with 
other solvents (methanol, ethanol, dimethylformamide, dichloromethane, ethyl acetate, Figure 3). 
The in vitro anti-MRSA data of the four isolated compounds represented in Table 4, 
showed the bacteriostatic activity of the isolated compounds against MRSA. In addition all 
metabolites were relatively inactive against other test organisms including the Gram-negative 
bacteria Escherichia coli and Pseudomonas aeruginosa, as well as the other microorganisms 
Mycobacterium intracellulare, Candida albicans, Cryptococcus neoformans, and Aspergillus 
fumigatus at a maximum concentration of 100 µg/mL. In vitro Vero cell (kidney fibroblast cells) 
cytotoxicity was not observed up to the maximum dose of 100 μg/mL. 
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        Table 4. In vitro antimicrobial activity of glycosides (1-4) 
compound 
MRSA S.  aureus 
IC50
a
 MIC
b 
 IC50
a
 MIC
b
 
1 1.99 +/- 0.58 10 +/- 0 3.72 +/- 0.86 13.33 +/- 4.71 
2 0.79 +/- 0.39 1.67 +/- 0.59 1.63 +/- 0.72 5.83 +/- 3.12 
3 0.73 +/- 0.03 1.25 +/- 0 1.41 +/- 0.05 3.75 +/- 1.25 
4 0.4 +/- 0.02 0.63 +/- 0 1.56 +/- 0.56 2.5 +/- 0 
Methicillin NA NA 0.45 +/- 0.07 2.5 +/- 0 
Piperacillin NA NA NT NT 
Ciprofloxacin 0.06 +/- 0.01 0.25 +/- 0 0.1 +/- 0.01 0.38 +/- 0.13 
 a
IC50 = the concentration that affords 50% inhibition of growth 
(µg/mL). 
b
MIC (minimum inhibitory concentration, µg/mL) is the 
lowest test concentration that allows no detectable growth. 
c
MBC 
(minimum bactericidal concentration) is the lowest test concentration 
that kills the organism (µg/mL). 
d
NA = not active at the highest test 
concentration. 
e
NT = not tested 
 
 
The structure-activity relationship of  the closely related compounds kaempferol 3-O-α-L-
(2'',4''-di-Z-p-coumaroyl)rhamnoside and kaempferol 3-O-α-L-(2''-Z-p-coumaroyl-4''-E-p-
coumaroyl)-rhamnoside show that the presence of the flavonoid moiety connected to the p-
coumaroyl functionality through the sugar as well as the presence of hydroxy groups at C-5, C-7, 
and C-4' are important for the anti-MRSA activity.
19
 Additionally, we found that the 
configuration of the double bonds of the p-coumaroyl units plays a significant role in the activity 
of these compounds. The Z-configured compound 4 shows enhanced activity in comparison with 
the E-configuration represented in E,E-platanoside 1 (MIC difference is ~ 9x). 
The in vivo results of E,E-platanoside 1 in Figure 4 showed that in the muscle tissue of 
untreated control animals (vehicle group) the MRSA cfu/g was 8.02 x 10
7
. The number of 
MRSA isolated from vancomycin-treated animals was 2.2 x 10
7
/g of tissue (p < 0.05), showing a 
reduction of 72% compared to the vehicle control. Similarly, the number of MRSA colonies 
 11 
recovered after treatment with E,E-platanoside 1 at 3 mg/kg and 15 mg/kg was 2.6 x 10
7
 and 1.8 
x 10
7
 respectively, which corresponded to a reduction of 67 (p < 0.05)  and 78% (p < 0.01)  as 
compared to the vehicle control. These results supported the in vitro data and indicated that the 
test compound was as active as vancomycin (3.0 mg/kg) against MRSA. While determining the 
maximal tolerated dose in the preliminary experiment, up to 20 mg/kg of E,E-platanoside 1 was 
given (i.p.), for 2 days. No adverse effect was seen in these animals indicating a lack of acute 
toxicity. Higher doses remain to be tested but based on the absence of detectable toxicity, the 
dosages could have been increased further. In summary, these plant natural products are highly 
promising drug leads for the control of MRSA and could be on par with the antibiotics currently 
used to treat drug-resistant Staph. aureus infections but with less potential for toxicity. 
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          Figure 2. The LC/MS analysis of the crude extract shows the presence of the four 
                                     metabolites 1-4 
 
 
 
 
         Figure 3. Stability of Z,Z-platanoside in various solvents 
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Figure 4. Effect of E,E-platanoside 1 on MRSA thigh infection in a murine model. Treatment with E,E-platanoside 
1 was initiated 2 h intraperitoneally after thigh inoculation. Thigh muscle homogenate was processed for 
microbiological  assay to determine the number of MRSA cfu/g of muscle tissue (n = 4) 
 
 
 
Experimental Section:                  
 General Experimental Procedures. Optical rotations were measured using a Rudolph 
Research Analytical Autopol IV automatic polarimeter model 589-546. UV spectra were 
recorded on a Varian Cary 50 Bio UV-visible spectrometer. The 1D and 2D NMR experiments 
were measured on a Bruker AV NMR spectrometer (Bruker Biospin, Bruker Inc.) operating at 
400 MHz and the chemical shift (δ) values are expressed in ppm. The mass spectra were 
measured using the Bruker micrOTOF (Bruker Daltonics, Bruker Inc.) with an ESI ionization 
source. HPLC was carried out on a Waters Prep-LC with a 2487 dual absorbance detector. 
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 Plant Material. The leaves and stem of P. occidentalis were collected in August 2007 in 
Oxford, Mississippi, and were identified by Dr. Charles Burandt. A voucher specimen (No. MI-
SYC-04-08) is housed at the Department of Pharmacognosy, School of Pharmacy, The 
University of Mississippi. 
Extraction and Isolation.  Air-dried leaves and branches (10 Kg) of different sizes were 
macerated at room temperature with ethanol yielding 400 g extract residue. The ethanolic extract 
(50 g) was subjected to silica gel vacuum-liquid chromatography (VLC), yielding an active 
fraction with EtOAc-MeOH (75:25) (7 g); Scheme 1. Bioassay-guided fractionation and 
purification of this fraction utilized HPLC at room temperature, a Luna C8 column (250 × 150 
mm, Phenomenex, Inc.), using H2O-CH3CN (100→100, 90 min, λ 300 nm) in which the active 
fraction eluted with H2O-CH3CN (5:95, 85 min); Scheme 2. Following this, a Luna NH2 column 
(250 × 21.20 mm, Phenomenex, Inc.) was used with n-hexane-CH2Cl2 (100→100, 30 min) and 
then CH2Cl2-MeOH (100→100, 30 min, λ 300 nm), yielding three well-resolved signals. All of 
the signals eluted with 100% MeOH: the first at 65 min (1) (20 mg), the second representing two 
metabolites at 77 min (2 and 3) (10 mg), and the third at 101 min (4) (3 mg); Scheme 3; Figure 5. 
Final purification of glycosides 2 and 3 was done using a PFP-2 (pentafluorophenyl) (250×10 
mm, Phenomenex Inc.) column with CH3CN-H2O (0→100, 120, λ= 300 nm). Glycosides 2 and 3 
eluted with CH3CN-H2O (50:50, λ= 300 nm) with retention times of 90 and 91 min, respectively; 
Figure 6. These four glycosides together represent 0.02-0.05% of leaf dry weight and the 
percentage of each individual glycoside is 65:25:3:7, respectively.  
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 E,E-platanoside (1): amorphous, off-white solid; [α]25D +89.6 (c 0.3, MeOH); UV 
(MeOH) λmax (log ε) 268 (4.4), 313 (4.6) nm;
 1
H NMR and
 13
C NMR, see Tables 2 and 3;  (+)-
(+)-HRESIMS m/z calcd for C39H33O14Na [M+Na]
+
 747.1684, found 747.1664; Figures (7-14). 
 E,Z-platanoside (2): amorphous, off-white solid; [α]25D +90.7 (c 0.2, MeOH); UV 
(MeOH) λmax (log ε) 267 (4.4), 314 (4.6) nm; 
1
H NMR and
 13
C NMR, see Tables 2 and 3; (+)-
HRESIMS m/z calcd for C39H33O14 Na [M+Na]
+
 747.1684, found 747.1667; Figures (15-22).  
 Z,E-platanoside (3): amorphous, off-white solid; UV (MeOH) λmax (log ε) 268 (4.5), 313 
(4.7) nm; 
1
H NMR and
 13
C NMR, see Tables 2 and 3; (+)-HRESIMS m/z calcd for C39H32O14 Na 
[M+Na]
+
 747.1684, found 747.1679; Figures (23-30).  
Z,Z-platanoside (4): amorphous, yellowish-white solid; [α]25 +16.7 (c 0.1, MeOH); UV 
(MeOH) λmax  (log ε) 267 (4.1), 313 (4.2) nm; 
1
H NMR and
 13
C NMR, see Tables 2 and 3; (+)-
HRESIMS m/z calcd for C39H32O14 Na [M+Na]
+
 747.1684, found 747.1647; Figures (31-38).  
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Scheme 1. Large scale fractionation of 50 gm sycamore ethanolic extract using VLC, 
blue color indicated the presence of the platanosides 
 
 
 
         Scheme 2. Application of Fr. 5; EtOAc-MeOH (75:25) on 250 x 100 mm C8 column, 
blue color indicated the presence of the platanosides 
 17 
 
                     Scheme 3. Application of Fr. 7; H2O-CH3CN (5:95) on 250 x 21.2 mm NH2 column, 
blue color indicated the presence of the platanosides 
 
 
         Figure 5. HPLC chromatogram of Fr. 7; H2O-CH3CN (5:95) on 250 x 21.2 mm NH2 
column 
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         Figure 6. HPLC chromatogram of signal 2 on 250 x 10 mm PFP-2 column 
 
 
 
 
 
        Figure 7. LC/MS chromatogram of E,E-platanoside 
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         Figure 8. 
1
H NMR spectrum of E,E-platanoside in methanol-d4 (600 MHz); A) the full 
spectrum, B) the downfield region 
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        Figure 9. 
13
C NMR spectrum of E,E-platanoside in methanol-d4 (600MHz); A) the full 
spectrum, B) the downfield region 
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         Figure 10. 135º DEPT spectrum of E,E-platanoside in methanol-d4 (600 MHz); A) the 
full spectrum, B) the downfield region 
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         Figure 11. HSQC spectrum of E,E-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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        Figure 12. COSY spectrum of E,E-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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          Figure 13. HMBC spectrum of E,E-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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              Figure 14. Selected COSY and HMBC correlations of E,E-platanoside 
 
 
           Figure 15. UV spectrum of E,Z-platanoside in MeOH 
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         Figure 16. 
1
H NMR spectrum of E,Z-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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         Figure 17. 
13
C NMR spectrum of E,Z-platanoside in methanol-d4 (400 MHz); A) the 
full spectrum, B) the downfield region 
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          Figure 18. 135º DEPT spectrum of E,Z-platanoside in methanol-d4 (400 MHz); A) the 
full spectrum, B) the downfield region 
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          Figure 19. HMQC spectrum of E,Z-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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           Figure 20. COSY spectrum of E,Z-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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         Figure 21. HMBC spectrum of E,Z-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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         Figure 22. NOESY spectrum of E,Z-platanoside in methanol-d4 (400 MHz) 
 
 
 
 
 
          Figure 23. UV spectrum of Z,E-platanoside in MeOH  
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         Figure 24. 
1
H NMR spectrum of Z,E-platanoside in methanol-d4(400 MHz); A) the full 
spectrum, B) the downfield region 
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         Figure 25. 13C NMR spectrum of Z,E-platanoside in methanol-d4 (400 MHz); A) the 
full spectrum, B) the downfield region 
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        Figure 26. 135º DEPT spectrum of Z,E-platanoside in methanol-d4 (400 MHz); A) the 
full spectrum, B) the downfield region 
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          Figure 27. HMQC spectrum of Z,E-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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         Figure 28. COSY spectrum of Z,E-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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          Figure 29. HMBC spectrum of Z,E-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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          Figure 30. NOESY spectrum of Z,E-platanoside in methanol-d4 (400 MHz) 
 
 
 
 
         Figure 31. UV spectrum of Z,Z-platanoside in MeOH  
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  Figure 32. 
1
H NMR spectrum of Z,Z-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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        Figure 33. 13C NMR spectrum of Z,Z-platanoside in methanol-d4 (400 MHz); A) the 
full spectrum, B) the downfield region 
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          Figure 34. 135º DEPT spectrum of Z,Z-platanoside in methanol-d4 (400 MHz); A) the 
full spectrum, B) the downfield region 
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          Figure 35. HMQC spectrum of Z,Z-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
 44 
 
 
 
 
 
 
          Figure 36. COSY spectrum of Z,Z-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
 45 
 
 
 
 
 
 
  Figure 37. HMBC spectrum of Z,Z-platanoside in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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          Figure 38. NOESY spectrum of Z,Z-platanoside in methanol-d4 (400 MHz)  
 
 
 
Carbohydrate Analysis. Each glycoside (0.3 mg) was hydrolyzed with 2 N HCl (1.0 
mL) for 3 h at 95 
o
C, cooled, neutralized with NH4OH, and extracted using EtOAc/H2O. The 
aqueous layer was dried, and dissolved in a mixture of pyridine (0.3 mL) and a 0.1 M solution of 
L-cysteine methyl ester hydrochloride in pyridine (1.0 mL). The reaction mixture was heated for 
1 hr at 60 
o
C, and an equal volume of Ac2O was added with continuous heating for an extra hour.  
The acylated thiazolidine derivatives were subjected to GC analysis [capillary column: DB-5 ms 
(30 m x 0.25 mm x 0.25 μm)].20,21 The carbohydrates were identified as L-rhamnose by 
comparison with the retention time of an L-rhamnose standard. 
 Antimicrobial Assays.  The CLSI (formerly NCCLS) method
22
 was used for the in vitro 
evaluation of test samples. Duplicate samples were transferred to 96-well microplates after 
diluting with 0.9% saline. The microbial cell suspensions were added to the samples to give the 
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required target inocula after addition to the samples. Media and solvent controls were included in 
each assay. The IC50 value was calculated by plotting percent growth versus test concentration.
23 
 
In Vivo MRSA Assay.
24
 Mice (CD-1) were purchased from Harlan, Inc. (Houston, TX) 
and acclimatized up to 5 days before the test. Food and water were available ad libitum 
throughout the study. The mice were rendered neutropenic by two injections of 
cyclophosphamide (100 mg/kg) given intraperitoneally (i.p.), one and four days before infection. 
A volume of 50 µL suspension of MRSA (1.5x10
6
 live organisms) was injected intramuscularly 
(im) into each of the two rear thighs. Each thigh was considered as an individual data point (a 
total of four data points for each treatment). These mice were randomly distributed into the 
control or treatment groups (n = 2/group). 
Treatment with E,E-platanoside 1 (i.p.) was initiated 2 h after thigh inoculation. Control 
animals were concurrently administered saline (mock treatment) or vancomycin in the same 
volume as those receiving E,E-platanoside 1. All animals were sacrificed after 48 h by CO2 
inhalation. Immediately following sacrifice, thigh tissue was collected from the animals, 
weighed, and homogenized in 5.0 mL of saline. Thigh muscle homogenate was processed for 
microbiological assay to determine the number of MRSA cfu/g of muscle tissue.
24,25 
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CHAPTER II 
 
PHOTOISOMERIZATION AS A MECHANISM TO ENHANCE BIOLOGICAL ACTIVITY 
AND CONTROL RESISTANCE IN STAPHYLOCOCCUS AUREUS AND METHICILLIN-
RESISTANT STAPHYLOCOCCUS AUREUS  
 
 
       Bay Leaves           American Sycamore
 49 
Recently, our research group reported
26
 the isolation and characterization of a group of 
four closely related anti-MRSA acylated kaempferol glycosides (platanosides); (Figure 1), 
isolated from Platanus occidentalis (American sycamore). We emphasized in our previous work 
the impact of changing the configuration from E- to Z- in the p-coumaric units on MRSA 
activity. We also showed that the isomerization from the kinetically favored Z,Z-platanoside (4) 
(IC50 0.75 µg/mL) to the thermodynamically stable E,E-platanoside (1) (IC50 6.16 µg/mL) was 
facilitated by an aqueous environment.   
 Here we report a simple, economical, and scalable “green” approach to transform the less 
active metabolite compound (1) to the most active metabolites (2-4) with the emphasis on the 
mechanism of isomerization and the biosynthesis of these metabolites. A similar approach was 
shown in 2008 by Fortin et al.
27
 Fortin pointed out that photo-switchable affinity label (PAL) 
treatment in endogenous ion channels that do not rely on exogenous gene expression confers 
light sensitivity onto endogenous K+ channels permitting the change in configuration from E- 
azobenzene derivatives to the Z-isomers in isolated rat neurons, allowing rapid optical regulation 
of excitability without genetic modification. Moreover, Jiang reported the discovery of a 
bacterial photoreceptor similar to photoactive yellow protein, which is a 4-hydroxycinnamic 
acid-containing protein that functions as a blue-light photoreceptor in a behavioral avoidance 
response in the organism.
28
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RESULTS 
SAR comparison between Platanus occidentalis and Laurus nobilis metabolites 
 Structural activity relationships were completed for this group of metabolites (1-4) 
relative to a closely related set of regioisomers isolated from Laurus nobilis, commonly called 
bay laurel or sweet bay. Leaves of bay laurel were shown by Otsuka et al., to possess anti-MRSA 
activity,
19 
(Figures 39 and 40); kaempferol 3-O-α-L-(2'',4''-di-E-p-coumaroyl)rhamnoside (5); 
(Figures 40, 41-47), and kaempferol 3-O-α-L-(2''-Z-p-coumaroyl-4''-E-p-coumaroyl)rhamnoside 
(6); (Figures 40, 48-49). Similar isolation schemes to those used for American sycamore were 
applied to bay leaves (Schemes 4 and 5).   
 The six isomers were shown by (+)-HRESIMS to possess similar masses with m/z 
747.1647-747.1679, indicating the molecular formula to be C39H32O14Na [M+Na]
+. Structure 
assignment of the isolated glycosides was confirmed by examination of 
1
H and 
13
C NMR data 
and comparison with the reported data.
19
 The anti-MRSA effects of the six metabolites 
confirmed the importance of changing the configuration on the Staph. aureus and MRSA activity 
as established by Ibrahim et al.
26
 Z,Z-platanoside (4) shows an IC50 0.75 µg/mL while E,E-
platanoside (1) shows an IC50 6.16 µg/mL, (Table 5). Interestingly, changing the regiochemistry 
on the rhamnose moiety from (2, 3) to (2, 4) was shown to be crucial for MRSA activity where 
kaempferol 3-O-α-L-(2'',4''-di-E-p-coumaroyl)rhamnoside (5) shows an IC50 0.53 µg/mL 
compared to 6.16 µg/mL for compound (1); (Table 5). 
For a better understanding of the SAR of the isolated glycosides, the commercially 
available quercitrin (7) and E-p-coumaric acid (8) as two primary moieties in the glycoside 
structures, (Figure 40), were tested against MRSA and Staph. aureus, (Table 5). Both 
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compounds did not show any recognizable activity against MRSA and Staph. aureus. The 
kaempferol glycoside should be acylated with at least one p-coumaroyl unit and this is consistent 
with what was reported by Otsuka et al. in the MRSA activity of compounds (5) and (6), referred 
to as 2,4-E,E-platanoside and 2,4-Z,E-platanoside.
19 
A similar trend was shown when evaluating 
these metabolites against Enterococcus faecalis (Table 5), where E,E and Z,Z-platanosides (1) 
and (4) show IC50 values of 11.15 and 2.67 µg/mL, respectively. Parallel with MRSA, changing 
the regiochemistry of the rhamnose moiety from (2, 3) to (2, 4) affects E. faecalis activity to a 
great extent, where 2,4-E,E-platanoside (5) shows an IC50 value of 3.09 µg/mL compared to 
11.15 µg/mL for E,E-platanoside (1), (Table 5). 
 
 
 
 
                 Figure 39. LC/MS comparison between American sycamore and bay leaves 
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                                  Figure 40.  Structures of Laurus nobilis metabolites, quercitrin, 
and E-p-coumaric acid 
 
 
Scheme 4. Fractionation of 3.5 g bay leaves ethanolic extract using VLC, blue color 
indicated the presence of the bay leaf glycosides 
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Scheme 5. Fractionation of Fr. 3; Hex-EtOAc (25:75) on 250 x 21.2 mm NH2 column, 
blue color indicated the presence of the bay leaf glycosides 
 
 
 
 
       Figure 41. LC/MS chromatogram of 2,4-E,E-platanoside  
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        Figure 42. Final purification of 2,4-E,E-platanoside on 250 x 21.2 mm NH2 column  
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         Figure 43. 
1
H NMR spectrum of 2,4-E,E-platanoside in methanol-d4 (400 MHz); A) 
the full spectrum, B) the downfield region 
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  Figure 44. 
13
C NMR spectrum of 2,4-E,E-platanoside in methanol-d4 (400 MHz); A) 
the full spectrum, B) the downfield region 
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           Figure 45. 135º DEPT spectrum of 2,4-E,E-platanoside in methanol-d4 (400 MHz); A) 
the full spectrum, B) the downfield region 
 58 
 
 
 
 
 
 
  Figure 46. HSQC spectrum of 2,4-E,E-platanoside in methanol-d4 (400 MHz); A) the 
full spectrum, B) the downfield region 
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  Figure 47. HMBC spectrum of 2,4-E,E-platanoside in methanol-d4 (400 MHz); A) the 
full spectrum, B) the downfield region 
 60 
 
 
 
 
 
 
           Figure 48. 
1
H NMR spectrum of 2,4-Z,E-platanoside in methanol-d4 (400 MHz); A) the 
full spectrum, B) the downfield region 
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Figure 49. 
13
C NMR spectrum of 2,4-Z,E-platanoside in methanol-d4 (400 MHz); A) the 
full spectrum, B) the downfield region 
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Isomerization of Z,Z-Platanoside (4) in Aqueous Medium. 
 During the isolation process, we encountered some difficulties due to rapid isomerization 
of the most active metabolite, Z,Z-platanoside (4) in aqueous medium to the less active 
metabolites (1-3). This, in turn, agrees with what was reported by Leenders et al.
29
 Leenders 
showed that the solvation of p-coumaric acid in water increases its polarization which in turn 
facilitates its isomerization rate.  A similar trend was shown for Z,Z-platanoside (4),  (Figure 3).  
Alkylation of E,E-Platanoside (1).  
 We investigated the alkylation route as a possible method to disrupt the conjugation 
demonstrated in Figure 50 by decreasing the electron-flow that was assumed to cause Z- to E- 
isomerization in the most active Z,Z-platanoside (4) as well as a possible means to increase the 
activity of the less active isomer (1). Various alkylating agents were utilized, including
 
methyltrifluoromethanesulfonate, without success.  
 
 
 
 
 
 
 
                                        
              Figure 50.  Possible conjugation in Z,Z-platanoside  
 
 
 Finally, utilizing methyl iodide in the presence of DMF containing K2CO3 and stirring at 
room temperature for 5-6 days yielded 10-15% alkylated product (Scheme 6). The purified 
methylated E,E-platanoside (9), (Figures 51-54), was shown by (+)-ESIMS to possess a mass 
with m/z 803.2; inferring the formula to be C43H40O14Na [M+Na]
+
, matched with the 
introduction of four methyl groups. Structure assignment was confirmed by examination of 1D 
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1
H and 
13
C NMR spectra as well as the 2D HSQC and HMBC data, where the four (O-methyl 
groups) show HMBC correlations to C-7, C-4' and the C-7''' (X2). The product, shown to be 
inactive in the MRSA assay, suggested the importance of the presence of free (OH-groups) 
groups at any or both of these positions for the MRSA activity. 
 
 
 
 
 
 
 
 
 
   Scheme 6.  Alkylation of E,E-platanoside  
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        Figure 51. Purification of tetra-O-methyl-E,E-platanoside (9) on 250 x 10 mm Si HPLC 
column 
 
 
 
 
         Figure 52. LC/MS chromatogram of tetra-O-methyl-E,E-platanoside (9) 
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                 Figure 53. 1H NMR spectrum of tetra-O-methyl-E,E-platanoside (9) in methanol-d4  
  (400 MHz) 
 
 
 
                     Figure 54. Selected HMBC correlations of tetra-O-methyl-E,E-platanoside (9) in 
methanol-d4 (500 MHz) 
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    Table 5.  In vitro antimicrobial activity of compounds 1-9  
 
Compound 
MRSA 33591 Staph.  aureus 29213 E. faecalis 29212 
IC50 MIC MBC IC50 MIC MBC IC50 MIC MBC 
(1) 6.16 NA NA 5.77 NA NA 11.15 20 NA 
(2) 1.93 8.33 NA 2.65 10.00 NA 3.38 10.00 NA 
(3) 1.46 6.67 NA 2.85 10.00 NA 3.10 5.00 NA 
(4) 0.75 2.08 NA 1.72 5.00 NA 2.67 5.00 NA 
(5) 0.53 1.67 NA 0.46 1.25 NA 3.09 10.00 NA 
(6) 0.73 1.67 NA 0.63 1.67 NA 3.25 6.67 NA 
(7) NA NA NA NA NA NA - - - 
(8) NA NA NA NA NA NA - - - 
(9) NA NA NA NA NA NA - - - 
Methicillin NA NA NA 0.43 1.56 1.56 20.52 50.00 50.00 
Erythromycin NA NA NA 0.16 0.63 1.25 3.85 5.00 5.00 
Ciprofloxacin 0.12 0.58 0.67 0.09 0.33 0.42 0.41 0.83 NA 
                   IC50 = the concentration that affords 50% inhibition of growth (µg/mL); MIC 
(Minimum Inhibitory Concentration µg/mL) is the lowest test concentration that allows no 
detectable growth; Minimum Bactericidal Concentration (MBC) is the lowest test 
concentration that kills the organism (µg/mL). NA = not active at the highest test 
concentration (20 µg/mL). (-), not tested. 
 
Light-Activated Isomerization of E,E-Platanoside (1)  
 From the previous set of in vitro data, it is clear that the key transformation to improve the activity is 
to transform the less active E-isomer (1) to the most active Z-isomers (2-4). There was an urgent need for this 
transformation, especially after these compounds showed an impressive ability to inhibit MRSA growth on 
contaminated surfaces similar to those present in hospitals (a Thin Layer Chromatograpghy plate; TLC is 
used as a model surface) (Figure  55), which encouraged Triton Biopharma AG to file a patent for this group 
of metabolites for controlling MRSA.  
 Numerous trials were conducted to achieve this required isomerization utilizing commercially 
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available E-p-coumaric acid as a model compound, considering that the Z-p-coumaric is not available 
commercially. Finally we achieved a 10-20% yield of Z-p-coumaric acid using a simple green chemistry 
approach via UV irradiation at 365 nm / methanol-d4 for 4-6 h. Applying the same procedure for the less 
active E,E-platanoside (1) enabled us to produce 10-15% of the most active isomers (2-4) after irradiation at 
365 nm / methanol-d4 for 12 h. The formation of the other three active metabolites may readily be detected 
by LC/MS spectrum (Figure 56). By extending the reaction time from 12 to 24 h, the yield of isomerization 
was improved by 20%. 
 
 
 
 
             Figure 55. Application of 0.5% mixture platanosides (1-4) on TLC plates contaminated 
with MRSA  
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 Chlorophyll has been shown previously to be a natural photosynthetizer.
30
 One of our goals was to 
evaluate the role of chlorophyll in controlling the photoisomerization process. For this study, commercially 
available E-p-coumaric acid was used as a model, and chlorophylls (a, b) were isolated from American 
sycamore according to the simple approach reported by Iriyama et al.
31
 Interestingly, UV-irradiation of a 
mixture of 90% E-p-coumaric and 10% chlorophylls (a, b) shows inhibition of the isomerization process with 
an overall yield of 4-6 % (Figure 57). The same result has been obtained by applying the same conditions to 
compound (1). This supports the hypothesis that the antioxidant properties of chlorophyll stabilize the 
equilibrium between the isolated isomers (1-4). 
 This “green” approach for increasing the activity was shown to be highly important as far as the 
amount of plant extract needed to produce the most active metabolites. Interestingly, these data supported the 
light mediated-biosynthetic formation of the Z-isomers (2-4) through two possible pathways. The first 
pathway involved UV-induced isomerization of E- to Z-p-coumaric acid, followed by acylation of the 
kaempferol glycoside. The second pathway involves UV irradiation of glycoside (1) or (5) to produce 
metabolites (2-4, and 6); (Figure 58) without genetic modification. 
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        Figure 56. The formation of the three active metabolites (2-4) through UV irradiation of E,E-platanoside  
 
 
              Figure 57. Effect of chlorophyll on the isomerization of E-p-coumaric acid, the Z-signal  
                                showed up at 5.5-5.7 ppm 
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                Figure 58. The suggested biosynthetic formation of the Z-metabolites (2-4) 
 
 The effect of solvent on the isomerization process was studied by conducting the isomerization in 
various protic and aprotic solvents (Figure 59). The results confirmed the importance of protic solvents for 
H-bond formation to facilitate the polarization of E-p-coumaric acid which in turn facilitates the 
isomerization process. These data are consistent with that reported in 2009 by Sigala et al.,
32
 showing the 
hydrogen bond dynamics in the active site of photoactive yellow protein. 
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  Figure 59. Effect of solvent (H-bonding) on the isomerization of E-p-coumaric acid, the Z-
signal showed up at 5.5-5.7 ppm 
 
 The mechanism of the isomerization was tested for the presence of a radical intermediate utilizing 
butylated hydroxytoluene (BHT), a common radical capture compound. However, no radical species could 
be detected (Figure 60), suggesting the absence of a radical mechanism and the possibility of an sp
2
-sp
3
 
carbon-interchange mechanism. 
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    Figure 60. Effect of BHT on the isomerization of E-p-coumaric acid 
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Discussion 
Platanosides have shown importance as drug leads with a high safety margin especially against 
methicillin-resistant Staphylococcus aureus (MRSA).
26
 Table 5 shows the bacteriostatic activity of the 
isolated compounds (1-6) against MRSA. In addition, all metabolites were relatively inactive against other 
test organisms, including the Gram-negative bacteria Escherichia coli and Pseudomonas aeruginosa, as well 
as other microorganisms Mycobacterium intracellulare, Candida albicans, Cryptococcus neoformans, and 
Aspergillus fumigatus at maximum concentrations of 100 µg/mL, confirming the selectivity of this group of 
metabolites. In vitro Vero cell (kidney fibroblast cells) cytotoxicity was not observed up to the maximum 
dose of 100 μg/mL. The effect of changing the olefinic configuration in the p-coumaroyl units or changing 
the regiochemistry in the sugar moiety, was confirmed to be crucial for the Staph.aureus and MRSA 
activities. The rapid isomerization of the most active and least stable metabolites to the less active ones 
hampered the use of this group of compounds as drug candidates. We addressed these major obstacles, 
demonstrating a simple and clean approach to enhance the activity (5≈10 times) against MRSA that may 
improve the marketing of these compounds.  
Methods  
 General Experimental Procedures.  The 1D and 2D NMR spectra were measured on a Bruker AV 
NMR spectrometer (Bruker Biospin, Bruker Inc.) operating at 400 MHz, and the chemical shift (δ) values are 
expressed in ppm. Mass spectra were measured using a Bruker micrOTOF (Bruker Daltonics, Bruker Inc.) 
with an ESI ionization source. HPLC was carried out on a Waters Prep-LC with a 2487 dual absorbance 
detector. 
Isolation and Purification of Metabolites (1-6). The leaves and stems of P. occidentalis were 
collected in August 2008 from the University of Mississippi Field Station, Oxford, MS. Laurus nobilis 
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leaves were purchased from American Mercantile Corporation in Memphis, TN. One kilogram of air-dried 
leaves of P. occidentalis was extracted at room temperature with EtOH (95%) yielding 50.0 g of extract 
residue. Fifty grams of the ethanolic extract were subjected to silica gel vacuum-liquid chromatography 
(VLC), yielding an active fraction from the EtOAc-MeOH (75:25) (7 g) eluate. Bioassay-guided 
fractionation and purification of this fraction utilized HPLC at room temperature, a Luna C8 column (250 × 
150 mm, Phenomenex, Inc.), using H2O-CH3CN (100→100, 90 min, λ 300 nm) in which the active fraction 
eluted with H2O-CH3CN (5:95, 85 min). Following this, a Luna NH2 column (250 × 21.20 mm, 
Phenomenex, Inc.) was used with n-hexane-CH2Cl2 (100→100, 30 min) and then CH2Cl2-MeOH (100→100, 
30 min, λ 300 nm), yielding three well-resolved signals. All of the signals eluted with 100% MeOH: the first 
at 65 min (1) (20 mg), the second representing two metabolites at 77 min (2 and 3) (10 mg), and the third at 
101 min (4) (3 mg). Final purification of glycosides 2 and 3 was done using a PFP-2 (pentafluorophenyl) 
(250×10 mm, Phenomenex Inc.) column with CH3CN-H2O (0→100, 120, λ= 300 nm). Glycosides 2 and 3 
eluted with CH3CN-H2O (50:50, λ= 300 nm) with retention times of 90 and 91 min, respectively. These four 
glycosides together represent 0.02-0.05% of leaf dry weight and the percentage of each individual glycoside 
is 65:25:3:7, respectively. A similar procedure was applied to 0.5 kg Laurus nobilis leaves, yielding the two 
metabolites (5 and 6) in about 20 mg and 15 mg respectively. 
Antimicrobial Assays.  The CLSI (formerly NCCLS) method
22
 was used for the in vitro evaluation 
of the test samples. Duplicate samples were transferred to 96-well microplates after diluting with 0.9% 
saline. The microbial cell suspensions were added to the samples to give the target inocula after addition to 
the samples. Media and solvent controls were included in each assay. The IC50 values were calculated by 
plotting percent growth versus test concentration.
23
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Alkylation of E,E-Platanoside (1). Compound (1) (7.5 mg, 0.01 mmol) was treated with excess 
methyl iodide in DMF containing K2CO3 and the mixture stirred for 5-6 days at room temperature resulted in 
the formation of 9 in 10-15% yield. Purification was done via Si-HPLC column with n-hexane/ EtOAc 
(100→100, 120 min, λ 300 nm) and a flow rate of 10 mL/min. The major compound had a retention time of 
40 minutes. The 
1
H NMR spectrum shows the presence of four O-methyl groups at 3.82, 3.84, 3.86 and 3.91 
ppm, with HMBC correlations to C-7, C-4' and the C- 7'''(X2).  
 TLC Demonstration of MRSA Activity of Mixture Glycosides (1-4). A 0.5% of mixture 
glycosides (1-4), (27% glycoside content by weight), was applied on TLC plates (4 cm x 4 cm) as model 
surfaces. The plates were dried overnight, the MRSA organism applied, incubated for 4-6 h, and stained with 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). The development of a purple color 
indicated growth. 
 Light-Activated Isomerization of Kaempferol E,E-Platanoside (1). Compound (8) was used as a 
model compound, where (16.4 mg, 0.01 mol) was dissolved in 200 µL methanol-d4 and irradiated at 365 nm 
for 4-6 h to produce Z-p-coumaric acid in 20-30% yield. Compound (1) (7.5 mg, 0.01 mmol) was subjected 
to the same conditions. Follow up on the reaction was done by acquiring the LC/MS and 
1
 H NMR spectra 
every 2 hours. The formation of the most active metabolites (2-4) was shown with a 10-15% yield. 
 Isolation of Chlorophyll from American Sycamore.  Fifty grams of fresh sycamore leaves were 
homogenized in 250.0 mL MeOH for 5.0 minutes. The resulting green extract was filtered through a cotton 
pad to remove coarse debris. The filtrate was centrifuged to remove any insoluble material. The green 
supernatant was mixed with dioxane (1:7 by volume) (35.0 mL). Distilled water was added dropwise under 
stirring until the mixture developed high turbidity. The mixture was placed in 0 ºC for one hour to promote 
precipitation. The thick dark green sediment at the bottom was collected by centrifugation. The crude 
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chlorophyll was dissolved in about 75.0 mL of methanol-dioxane mixture (7:1) by volume and re-
precipitated by dropwise addition of water. The same procedure was repeated to achieve further purification. 
 Effect of Chlorophyll on the Isomerization Process. Compound (8) was used as a model compound 
whereby it (16.4 mg, 0.01 mol) was mixed with 10% chlorophyll and dissolved in 200 µL CDCl3 and 
irradiated at 365 nm for 4-6 h to produce Z-p-coumaric acid in less than 10% yield. Compound (1) (7.5 mg, 
0.01 mmol) was mixed with 10% chlorophyll and dissolved in 200 µL methanol-d4 and irradiated at 365 nm 
for 12 h. Follow up of the reaction was achieved through acquiring the LC/MS and 
1
H NMR spectra every 2 
hours. The formation of the most active metabolites (2-4) was shown with around 5% yield.  
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CHAPTER III 
 
LINKING THE DISCOVERY OF LEADS FOR DRUG RESISTANT HUMAN PATHOGENS 
TO THE GENERATION OF DISEASE RESISTANT STRAINS OF PLATANUS 
OCCIDENTALIS (AMERICAN SYCAMORE) 
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Platanus occidentalis (American sycamore) [family: Platanaceae] is fairly widespread throughout the 
eastern United States, from Texas to Nebraska, Iowa to Wisconsin and into southern Ontario, Canada, and 
the mountains of northeastern Mexico.
33 
The tree can reach heights of 18-37 meters and diameters of 3-4 
meters. Native Americans used sycamore for various medical purposes including cough and cold remedies, 
dietary supplements, gynecological, dermatological, and gastrointestinal aids. American sycamore is 
important to the forest products industry because it grows well in short-rotation plantations and is used 
mainly for pulp and fiberboard; sawlogs are used to make butcher's blocks, furniture, interior trim, boxes, 
and flooring.
33
 The American sycamore is a fast growing tree with potential to be a dedicated biomass crop 
for fuel production. Howevere, the development, and thus the utility, of sycamore plantations for growing 
pulpwood, sawlogs, or biomass for biofuels is hampered by bacterial leaf scorch disease (BLS) caused by 
Xylella fastidiosa
33
 that greatly impedes wood production. By the early 2000s because of concerns over BLS, 
most industrial forest companies in the southeastern U.S. began liquidating their American sycamore stands 
in favor of less disease-prone hardwood species. In one study in Mississippi, nine-year old BLS-diseased 
trees were reduced 26% in height and 27% in diameter growth compared to healthy trees; volumes of 
diseased trees were 74% less than healthy trees (T. Leininger, unpublished data),  (Figure 61).
33 
Strains of X. fastidiosa cause various plant diseases such as phony peach disease (PPD), plum leaf 
scald (PLS), and Pierce's disease (PD) of grapevines, citrus variegated chlorosis (CVC), and leaf scorch of 
almond, oleander, pear, and several shade tree species such as American sycamore.
34a 
These diseases are 
common in the southeastern United States but also occur in California, southern Ontario, and some southern 
midwestern states. In north Florida, PPD and PLS were shown to limit peach and plum orchard life.
34a
 
Bacterial leaf scorch (BLS) diseases have similar etiologies and share similar symptoms in plum, oak, 
sycamore, and many other woody species, where the leaves appear normal early in the season but later 
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develop a tan colored interveinal and/or marginal necrosis that spreads toward the base of the leaf. Leaf 
necrosis results as X. fastidiosa multiplies and the bacteria clog leaf xylem tracheary elements preventing 
water from reaching individual cells. Water transport to leaves, twigs, and branches is disrupted by the 
bacteria and their by-products causing water stress that leads to pathogenesis. The bacterial infection also 
causes tyloses to form in xylem elements causing further disruption to plant tissue water supply.  
 A typical symptomatic sycamore leaf has a narrow green zone of tissue (5-15 mm) with an uneven 
border surrounding the midrib and main veins while the rest of the leaf blade is necrotic (Figure 61).
34b
 Initial 
foliar symptoms progress to branch dieback, which over a period of several years can lead to severe crown 
dieback, stem death and breakage, and eventual tree mortality. X. fastidiosa perennates in roots and moves 
yearly into the current year's xylem where it is transported to leaves.
34b
 Thus, leaves of infected trees appear 
healthy in spring but begin to express symptoms in early to mid summer. Severe foliar symptoms and new 
twig and branch dieback are evident by late summer and early fall. While some reports claim that bacterial 
leaf scorch occurrence has increased dramatically to epidemic levels in the last ten to fifteen years in the 
middle-Atlantic states,
34a
 BLS of American sycamore probably always has been common in the region. More 
likely, it became easier to identify BLS disease in the 1990's with the advent of a commercially available 
ELISA test that enabled clear detection of X. fastidiosa in diseased tissue. Furthermore, BLS of American 
sycamore may have become more common, especially in the southeastern U.S., when, beginning in the 
1990's, forest products industries began planting large acreages for pulpwood. 
Xylella fastidiosa (Xf) (Figure 62) grows slowly in culture and appears to to spread slowly up and 
down the xylem of the tree starting from the site of infection.
34a
 The bacterium enters the plant through grafts 
or insects feeding on xylem sap. The major insect vector in the southeastern United States is most likely the 
glassy-winged sharpshooter, Homalodisca vitripennis (Figure 63), but other sharpshooters of the subfamily 
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Cicadellinae, or other xylem-feeding insects, including froghoppers, of the spittlebug family Cercopidae, are 
also known to transmit the disease. Within the last 10 years, grape production in California has been 
threatened by Pierce's disease because of the introduction of the glassy-winged sharpshooter, which is 
endemic to the southeastern U.S.  Research into the ecological link between American sycamore tree health 
and platanoside content could potentially lead to remedies in controlling Pierce's disease and other X. 
fastidiosa-caused diseases.
34a 
 
 
 
              Figure 61. A sycamore leaf expressing symptoms of bacterial leaf scorch
34a
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                  Figure 62. A colony of Xylella fastidiosa 
34a 
 
 
 
 
 
              Figure 63. Homalodisca vitripennis, the glassy-winged sharpshooter 
34a
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Recently, we reported the isolation of a group of anti-MRSA metabolites from Platanus occidentalis 
(American sycamore). The four MRSA lead compounds are E,E-platanoside (1) (IC50 2.0 µg/mL), E,Z-
platanoside (2) (IC50 0.8 µg/mL), Z,E-platanoside (3) (IC50 0.7 µg/mL), and Z,Z-platanoside (4) (IC50 0.4 
µg/mL) Figure 64.
26
 The ecological role of these metabolites was investigated in relation to bacterial leaf 
scorch caused by X. fastidiosa that reduces the productivity of American sycamore plantations and greatly 
curtailed its use for pulpwood by industry. 
 
 
              Figure 64. Anti-MRSA metabolites from Platanus occidentalis (American sycamore)26 
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A Standard Operating Procedure (SOP) for determination of rhamnose glycosides from American 
sycamore leaves by LC/MS was established, and the calibration curve was determined based on E,E-
platanoside (1), Figure 65. 
 
 
                               Figure 65.  LC/MS calibration curve of E,E-platanoside  
 
Seven leaf samples (composed of 5-7 mature leaves each) from leaf scorch asymptomatic trees and 
seven symptomatic trees were provided in August 2009 through the collaboration with Dr. Theodor D. 
Leininger, Project Leader, USDA Forest Service, Southern Research Station, Center for Bottomland 
Hardwoods Research, Stoneville, MS. These samples were evaluated for their glycoside content as shown in 
Table 6 and Figure 66.    
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                           Table 6. Percent glycosides in 7 asymptomatic and 7 symptomatic American  
sycamore trees 
Tree  Code Health % glycosides  
4-11 0 0.39 
14-5 0 0.27 
11-11 0 0.20 
17-11 0 0.28 
17-19 0 0.21 
9-17 0 0.31 
14-19 0 0.19 
6-17 1 0.17 
8-13 1 0.24 
16-19 1 0.14 
4-5 1 0.23 
12-19 1 0.14 
18-12 1 0.14 
17-6 1 0.17 
“0”= leaf from leaf scorch asymptomatic tree; “1” = leaf from leaf scorch  
    symptomatic tree 
 
 
 
               Figure 66.  Percent glycosides in 7 asymptomatic and 7 symptomatic trees 
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Six samples were recollected in May 2010, re-assayed for their glycoside content, and the data were 
compared to those of August 2009 (Table 7). 
 
          Table 7. Glycoside content comparison between August 2009 and May 2010 for three asymptomatic and three 
symptomatic trees 
Tree Code Health % glycosides 
 (August 2009) 
% glycosides 
 (May 2010) 
4-11 0 0.39 0.45 
14-5 0 0.27 0.43 
9-17 0 0.31 0.52 
16-19 1 0.14 0.40 
18-12 1 0.14 0.41 
17-6 1 0.17 0.27 
 “0”= leaf from leaf scorch asymptomatic tree; “1” = leaf from leaf scorch symptomatic tree 
 
As shown in Table 7, some trees are showing consistently low content (i.e., 17-6), while others show 
consistently high content, like 9-17, suggesting a possible ecological link between these metabolites and 
resistance to X. fastidiosa. Pictures of both trees (Figure 67) show the severe BLS-diseased condition of tree 
17-6 with only one live basal shoot while tree 9-17 remains healthy. 
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             Figure 67. Picture of the two American sycamore trees coded 17-6 (BLS-symptomatic) and 9-17 (BLS-asymptomatic) 
 
 An in vitro bacteriocidal evaluation of these metabolites against X. fastidiosa was completed using 
the bacterium was obtained from Ruth Donaldson at the Department of Plant Pathology, University of 
Georgia, Griffin, GA. Bacterial cultures were maintained using CS20 specific medium. Two sets of 
experiments were performed: a) various concentrations of a semi purified mixture of glycosides (purity ≥ 
70% by LC/MS) were tested for their in vitro activity against X. fastidiosa and, b) the pure metabolites were 
evaluated for their in vitro activity against X. fastidiosa in the same Petri plates with the semi-purified 
mixture of glycosides (27% glycoside content by weight). Interestingly, glycoside mixture concentrations of 
0.2%, 0.1%, and 0.025% prevented X. fastidiosa growth. The 0.005% concentration did not prevent X. 
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fastidiosa growth (MIC ≤ 0.05 µg/mL) Figures 68 and 69. The data showed similar SARs to those 
demonstrated for MRSA, where the in vitro antibacterial activity of the Z,Z-platanoside was more effective 
against Xf (MIC ≤ 17 nM) than was shown for the E,E-platanoside (MIC ≤ 67 nM), Figures 70-72. In view of 
the information presented in the previous chapter, these data suggest a possible photochemical defense 
mechanism of American sycamore against X. fastidiosa infections. 
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           Figure 68. In vitro assay of 0.2, 0.1, and 0.025% range of semi purified mixture of glycosides (purity ≥ 
70% by LC/MS) against X. fastidiosa 
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             Figure 69. In vitro assay of 0.1, 0.025, and 0.005% range of semi purified mixture of glycosides (purity ≥ 70% by 
LC/MS) against X. fastidiosa in double compartment Petri plates (72 h) 
 
 
 
 
 
             
Figure 70. In vitro assay of 0.005-0.00125% of E,E-platanoside, Z,Z-platanoside, mixture of glycosides (27% 
purity by weight), and –ve control  in four compartment Petri plates 
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Figure 71. In vitro assay of 0.005-0.00125% of E,Z-platanoside, Z,E-platanoside, mixture of glycosides (27% 
purity by weight), and –ve control  in four compartment Petri plates 
 
 
 
Figure 72. In vitro assay of 0.005-0.0025% of E,E-platanoside, Z,Z-platanoside, Z,E-platanoside, and  E,Z-
platanoside in four compartment Petri plates 
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Experimental Section:                  
 General Experimental Procedures. The 1D and 2D NMR experiments were measured on a Bruker 
AV NMR spectrometer (Bruker Biospin, Bruker Inc.) operating at 400 MHz and the chemical shift (δ) values 
are expressed in ppm. The mass spectra were measured using the Bruker micrOTOF (Bruker Daltonics, 
Bruker Inc.) with an ESI ionization source. HPLC was carried out on a Waters Prep-LC with a 2487 dual 
absorbance detector. 
 Plant Material. The leaves of P. occidentalis were collected in August 2009 and May 2010 from the 
USDA Forest Service, Center for Bottomland Hardwoods Research, Stoneville, Mississippi and were dried 
under vacuum for about 2-4 h and then ground to small pieces by hand (particle size < 0.01 mm). 
Extraction and Isolation. Air-dried leaves and petioles (1.0 g) were extracted with 25 mL of EtOH 
(95%)-H2O (25:75) and shaken for 2 h to extract unwanted material. The active glycosides were extracted in 
25 mL of EtOH (95%)-H2O (75:25) by stirring for an additional 2 h. The active metabolite extraction was 
repeated three times. Finally, all the active extracts were combined. The solvent was evaporated using a 
rotavap at 40-45 
o
C, and the insoluble materials were removed by passing the extract solution through a 0.22 
µm filter. The dried extract was dissolved in 20 mL MeOH. A 100 µL sample was placed in an LC/MS vial 
and a 20 µl sample was injected using the gradient in Table 8 at 35 ºC. 
     Table 8. LC/MS program for determination of rhamnose glycosides 
Time (minute) H2O(0.05%)HCOOH MeOH(0.05%)HCOOH Flow rate (ml/min) 
0 90 10 0.6 
15 0 100 0.6 
30 0 100 0.6 
 
In Vitro Assay. X. fastidiosa was grown on a CS20 specific medium (soy peptone 2.0 g/L, bacto 
tryptone 2.0 g/L, (NH4)2HPO4 0.85 g/L, hemin Cl [(0.1% ), 15.0 mL/L], KH2PO4 1.0 g/L, MgSO4.7H2O 
0.4g/L, L-glutamine 6.0 g/L, dextrose 1.0 g/L, starch (potato soluble) 2.0 g/L, L-histidine 1.0 g/L, phenol red 
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[(0.2%) 5.0 mL/L], and 14.0 g/L agar). The pH
 
was adjusted to be in the range of 6.6-6.7. For experiment (a), 
the crude mixture of glycosides was subjected to semi purification [50-100 mg extract loaded on SPE, Strata 
C18-E (55 µm, 70 A), (1000 mg/6 mL) - Phenomenex, eluted with H2O-CH3CN(100:0 → 0:100), 25% 
increment, 3 bed volumes each, the glycosides eluted mainly in H2O-CH3CN (25:75)], while for experiment 
(b), no further purification was applied to the crude mixture. 
a) A 0.2-0.005% concentration range of the semi purified mixture of glycosides (purity ≥ 70% by 
LC/MS) was tested for efficacy against X. fastidiosa by mixing each concentration with 20 mL of media to 
overcome the poor diffusion properties of these metabolites. The mixture of media and glycosides was 
autoclaved, poured into Petri plates, and cooled. The bacterium was streaked onto the agar surface and the 
plates were incubated for 72 h at 37 ºC.  
b) A 0.005-0.00125% concentration range of the mixture of glycosides (27% purity by weight) and 
the pure metabolites were tested for efficacy against X. fastidiosa by mixing each concentration with 15 mL 
autoclaved media, poured into Petri plates, and cooled. The bacterium was streaked onto the agar surface and 
the plates were incubated for 72 h at 37 ºC.  
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CHAPTER IV 
 
2-(5-HALO-1H-INDOL-3-YL)-N,N-DIMETHYLETHANAMINES AS ANTIDEPRESSANT 
DRUG LEADS 
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1. Introduction 
Depression is the most common disease of the central nervous system, affecting approximately 17% 
of Americans each year.
35
 According to National Institute of Mental Health (NIMH), about 40 million 
American adults suffer from anxiety disorders every year that frequently co-occur with other psychiatric 
illnesses, like depression.
36
 Both disorders are often treated with antidepressant medications. All currently 
available antidepressant drugs enhance the monoaminergic transmitter mechanism by inhibiting the 
metabolism or reuptake of certain neurotransmitters (serotonin or adrenaline) and increasing their 
concentration in the brain. However, the clinically-used antidepressants suffer from serious side effects and 
take approximately six weeks before the patient is able to experience the full therapeutic effect. Anxiety 
disorders can be also treated with sedative medications, which can cause addiction and other side effects like 
drowsiness, dizziness, and headaches. There is a clear need for more effective and safer drugs for depression 
and anxiety disorders. Recently, various marine natural products were reported as valuable drug leads for 
neurological disorders.
37
 
In previous studies, we isolated several marine indole alkaloids and evaluated them in the forced 
swim test (FST) and locomotor activity test, revealing their potentials to become new antidepressant and 
sedative drug leads.
37,38
 Among the reported neurological active compounds, 5-bromo-N,N-
dimethyltryptamine was found to exhibit strong sedative effect in the locomotor activity test.
37 
Because of 
limited amounts of the natural product, a synthetic approach was adopted to prepare 5-bromo-N,N-
dimethyltryptamine and its derivatives to study the structure activity relationships and complete the dose-
response experiments. The current study describes the preparation of various derivatives of 2-(1H-indol-3-
yl)-N,N-dimethylethanamine with different halogens in position 5 and the evaluation of  their activity in two 
animal models, forced swim and locomotor activity tests. The forced swim test is a well established animal 
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model assessing the potential clinical antidepressant action of drug.
39-41
 The locomotor activity test was used 
to confirm that the antidepressant action observed in the FST could not be attributed to a nonspecific 
stimulant activity of the tested compounds. A significant reduction in locomotor activity is usually predictive 
of a potential sedative action.  
2. Methods 
2.1. Subjects 
Experiments were performed using eight week old mice. Male Swiss Webster mice (Harlan, IN, 
USA) weighing 24-31 grams at the time of testing were used for the automated forced swim test. The mice 
were housed in groups of five with a 12 h light/12 h dark cycle. Food and water were provided ad libitum. 
All mice were randomly selected for each treatment group. Procedures involving animals were performed 
according to the guidelines approved by the Institutional Animal Care and Use Committee. 
2.2. Drugs 
 A series of 2-(5-halo-1H-indol-3-yl)-N,N-dimethyl-2-oxoacetamides and 2-(5-halo-1H-indol-3-yl)-
N,N-dimethylethanamines (Scheme 7) were synthesized via a straightforward and efficient approach.
42
 We 
have encountered problems associated with loosing the halogen in the last reduction step; however these can 
be eliminated by changing the solvent from THF, which is commonly used for these types of reactions, to 
DME and monitoring the reaction by either GC/MS or LC/MS.  
The synthesis of the haloindoledimethylethanamines began by conversion of halo-substituted indoles 
to the corresponding oxoacetyl chlorides via portionwise addition of oxalyl chloride in anhydrous diethyl 
ether at 0 
o
C, followed by stirring for one hour under inert atmosphere to provide 2a-e in (80-90%) yield as 
yellowish orange solids. The resulting oxoacetyl chlorides 2a-e were treated with dimethylamine solution 
(40% in water) at 0 
o
C for 30 minutes, followed by stirring for additional two hours at room temperature. 
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After extraction of the product with DCM, the white solid residues were further purified by HPLC using 
reverse-phase C8 column and H2O-MeOH solvent system to afford oxoacetamides 3a-e in (80-90%) yields. 
The final step of the synthesis was achieved by catalytic reduction of oxoacetamides 3 using LiAlH4 solution 
in anhydrous DME with sequential stirring of the mixture at 0 
o
C for one hour, at room temperature for two 
hours, and at 80 
o
C for six hours, respectively. After work up, the resulting yellowish-brown precipitate was 
collected and subjected to further purification using an HPLC C8 column and H2O-MeOH solvent system to 
give the anticipated ethyldimethylamines 4a-e in (65-75%) yields.  
 
N
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X
N
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Cl
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N
H
X
b
O
N
O
N
H
X
c
N
1a: X=H
1b: X=F
1c: X=Cl
1d: X=Br
1e: X=I
3a-e 4a-e2a-e
 
 
Scheme 7. The synthesis of 5-haloindoledimethylethanamines. Reagents and reaction conditions: (a) Oxalyl chloride, diethyl 
ether, 0 
o
C, 30-60 min, (80-90%); (b) Dimethylamine, 0 
o
C, 30 min, then rt, 2 h, (80-90%); (c)  LiAlH4, DME, 0 
o
C, 1 h, then rt, 2 
h, then 80 
o
C, 2 h, (65-75%). 
  
The structures of the synthesized compounds were established via
 
1D and 2D NMR experiments that 
were measured on a Bruker DRX NMR spectrometer operating at 400 MHz, and the chemical shift (δ) 
values are expressed in (ppm); (Figures 73-80). HPLC analysis was carried out on Waters instrument with a 
2487 dual absorbance detector. The molecular structure of oxoacetamide 3a in the solid state was confirmed 
by X-ray analysis. A suitable single crystal of non-halogenated compound 3a was obtained by slow 
evaporation of a concentrated solution in methanol. The crystal structure and the crystallographic numbering 
are shown in Figure 81. 
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        Figure 73. 
1
H NMR spectrum of 2-(5-fluoro-1H-indol-3-yl)-N,N-dimethyl-2-
oxoacetamide (3b) in methanol-d4 (400 MHz) 
 
 
            Figure 74. 
13
C NMR spectrum of 2-(5-fluoro-1H-indol-3-yl)-N,N-dimethyl-2-
oxoacetamide (3b) in methanol-d4 (400 MHz) 
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           Figure 75. 135º DEPT spectrum of 2-(5-fluoro-1H-indol-3-yl)-N,N-dimethyl-2-
oxoacetamide (3b) in methanol-d4 (400 MHz) 
 
 
 
             Figure 76. 
1
H NMR spectrum of 2-(5-chloro-1H-indol-3-yl)-N,N-dimethyl-2-
oxoacetamide (3c) in methanol-d4 (400 MHz) 
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             Figure 77. 
13
C NMR spectrum of 2-(5-chloro-1H-indol-3-yl)-N,N-dimethyl-2-
oxoacetamide (3c) in methanol-d4 (400 MHz) 
 
 
 
            Figure 78. 135º DEPT spectrum of 2-(5-chloro-1H-indol-3-yl)-N,N-dimethyl-2-
oxoacetamide (3c) in methanol-d4 (400 MHz) 
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            Figure 79. GC/MS chromatogram of 2-(5-bromo-1H-indol-3-yl)-N,N-dimethyl-2-  
                                        oxoacetamide (3d) 
 
 
 
        Figure 80. 
1
H NMR spectrum of 2-(5-bromo-1H-indol-3-yl)-N,N-dimethyl-2-
oxoacetamide (3d) in CDCl3 (400 MHz) 
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Figure 81. The X-ray crystal structure of compound 2-(1H-
indol-3-yl)-N,N-dimethyl-2-oxoacetamide (3a) 
 
The 2-(1H-indol-3-yl)-N,N-dimethylethanamine (4a); C12H16N2, was purified as a brownish white 
precipitate, 
1
H NMR (methanol-d4), δ 1.61 (s, 6H), 1.99 (d, 2H), 2.35 (d, 2H), 6.41 (s, 1H), 6.56 (dt, 1H), 
6.85 (d, 1H), 7.06 (d, 1H). 
13
C NMR (methanol-d4), δ 24.11 (t), 45.66 (q), 61.01 (t), 112.39 (d), 113.54 (s), 
119.34 (s), 119.68 (d), 122.40 (d), 123.10 (d), 128.64 (s), 137.97 (s); (Figures 82-87). The 2-(5-fluoro-1H-
indol-3-yl)-N,N-dimethylethanamine (4b); C12H15N2F, was purified as a yellowish white precipitate, 
1
H 
NMR (methanol-d4), δ 1.79 (s, 6H), 2.97 (d, 2H), 3.12 (d, 2H), 6.74 (dt, 1H), 7.08 (s, 1H), 7.15 (m, 2H). 
13
C 
NMR (methanol-d4), δ 22.01 (t), 43.64 (q), 59.15 (t), 103.76 (d), 104.00 (s), 110.83 (s), 111.10 (d), 113.44 
(d), 113.54 (d), 126.16 (s), 134.86 (s); (Figures 88-90). The 2-(5-chloro-1H-indol-3-yl)-N,N-
dimethylethanamine (4c); C12H15N2Cl, was purified as a yellowish white precipitate,
 1
H NMR (methanol-d4), 
δ 2.36 (s, 6H), 2.70 (d, 2H), 2.91 (d, 2H), 5.93 (t, 1H), 6.99 (s, 1H), 7.24 (d, 1H), 7.47(s, 1H). 13C NMR 
(methanol-d4), δ 22.48 (t), 43.67 (q), 59.67 (t), 110.83 (d), 111.60 (s), 117.69 (s), 118.21 (d), 120.96 (d), 
121.83 (d), 127.15 (s), 136.79 (s); (Figures 91-95). The 2-(5-bromo-1H-indol-3-yl)-N,N-dimethylethanamine 
(4d); C12H15N2Br, was purified as a yellowish white precipitate, 
1
H NMR (methanol-d4), δ 2.191 (s, 6H), 
2.48 (d, 2H), 2.75 (d, 2H), 6.95 (s, 1H), 7.07 (d, 1H), 7.130 (d, 1H), 7.56 (s, 1H). 
13
C NMR (methanol-d4), δ 
24.11 (t), 45.46 (q), 61.39 (t), 112.88 (d), 113.57 (s), 114.05 (s), 121.88 (d), 124.86 (d), 125.14 (d), 130.59 
(s), 136.84 (s); (Figures 96-101). The 2-(5-iodo-1H-indol-3-yl)-N,N-dimethylethanamine (4e); C12H15N2I, 
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was purified as a  yellowish white precipitate, 
1
H NMR (methanol-d4), δ 2.21 (s, 6H), 2.53 (d, 2H), 2.82 (d, 
2H), 6.93 (s, 1H), 6.99 (t, 1H), 7.22 (d, 1H), 7.42 (d, 1H). 
13
C NMR (methanol-d4), δ 24.29 (t), 46.0 (q), 
61.80 (t), 112.41 (d), 113.66 (s), 119.30 (s), 119.77 (d), 122.42 (d), 123.22 (d), 128.75 (s), 138.25 (s); 
(Figures 102-104). 
 
 
              Figure 82. 
1
H NMR spectrum of 2-(1H-indol-3-yl)-N,N-dimethylethanamine (4a) in   
methanol-d4 (400 MHz) 
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            Figure 83. 
13
C NMR spectrum of 2-(1H-indol-3-yl)-N,N-dimethylethanamine (4a) in 
methanol-d4 (400 MHz) 
 
 
 
                Figure 84. 135º DEPT spectrum of 2-(1H-indol-3-yl)-N,N-dimethylethanamine (4a) in 
methanol-d4 (400 MHz) 
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                 Figure 85. HSQC spectrum of 2-(1H-indol-3-yl)-N,N-dimethylethanamine (4a) in 
methanol-d4 (400 MHz) 
 
 
 
                    Figure 86. HMBC spectrum of 2-(1H-indol-3-yl)-N,N-dimethylethanamine (4a) in 
methanol-d4 (400 MHz) 
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                  Figure 87. COSY spectrum of 2-(1H-indol-3-yl)-N,N-dimethylethanamine (4a) in 
methanol-d4 (400 MHz) 
 
 
 
                Figure 88. 
1
H NMR spectrum of 2-(5-fluoro-1H-indol-3-yl)-N,N-dimethylethanamine 
(4b) in methanol-d4 (400 MHz) 
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                 Figure 89. 
13
C NMR spectrum of 2-(5-fluoro-1H-indol-3-yl)-N,N-dimethylethanamine 
(4b)  in methanol-d4 (400 MHz) 
 
 
 
              Figure 90. 135º DEPT spectrum of 2-(5-fluoro-1H-indol-3-yl)-N,N-
dimethylethanamine (4b)  in methanol-d4 (400 MHz) 
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                  Figure 91. LC/MS chromatogram of 2-(5-chloro-1H-indol-3-yl)-N,N-
dimethylethanamine (4c)   
 
 
 
 Figure 92. 
1
H NMR spectrum of 2-(5-chloro-1H-indol-3-yl)-N,N-dimethylethanamine 
(4c) in methanol-d4 (400 MHz) 
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                Figure 93. 
13
C NMR spectrum of 2-(5-chloro-1H-indol-3-yl)-N,N-dimethylethanamine 
(4c) in methanol-d4 (400 MHz) 
 
 
 
                 Figure 94. 135º DEPT spectrum of 2-(5-chloro-1H-indol-3-yl)-N,N-
dimethylethanamine (4c) in methanol-d4 (400 MHz) 
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             Figure 95. HSQC spectrum of 2-(5-chloro-1H-indol-3-yl)-N,N-dimethylethanamine 
(4c) in methanol-d4 (400 MHz) 
 
 
 
                  Figure 96. LC/MS chromatogram of 2-(5-bromo-1H-indol-3-yl)-N,N-
dimethylethanamine (4d) 
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                        Figure 97. 
1
H NMR spectrum of 2-(5-bromo-1H-indol-3-yl)-N,N-dimethylethanamine 
(4d) in methanol-d4 (400 MHz) 
 
 
 
                              Figure 98. 
13
C NMR spectrum of 2-(5-bromo-1H-indol-3-yl)-N,N-dimethylethanamine 
(4d) in methanol-d4 (400 MHz) 
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                     Figure 99. 135º DEPT spectrum of 2-(5-bromo-1H-indol-3-yl)-N,N-
dimethylethanamine (4d) in methanol-d4 (400 MHz) 
 
 
 
                              Figure 100. HSQC spectrum of 2-(5-bromo-1H-indol-3-yl)-N,N-dimethylethanamine 
(4d) in methanol-d4 (400 MHz) 
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                          Figure 101. HMBC spectrum of 2-(5-bromo-1H-indol-3-yl)-N,N-dimethylethanamine 
(4d) in methanol-d4 (400 MHz); A) the full spectrum, B) the high field 
region 
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                Figure 102. 
1
H NMR spectrum of 2-(5-iodo-1H-indol-3-yl)-N,N-dimethylethanamine 
(4e) in  methanol-d4 (400 MHz) 
 
 
 
             Figure 103. 
13
C NMR spectrum of 2-(5-iodo-1H-indol-3-yl)-N,N-dimethylethanamine 
(4e)  in methanol-d4 (400 MHz) 
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               Figure 104. 135º DEPT spectrum of 2-(5-iodo-1H-indol-3-yl)-N,N-
dimethylethanamine (4e) in methanol-d4 (400 MHz) 
 
2.3 Forced Swim Test (FST) 
The FST is a model of behavioral despair whereby mice placed in an inescapable situation (in this 
case a cylinder of water) usually exhibit behavioral despair within two minutes of a six minute session. An 
antidepressant effect is elicited as a reduction in immobility duration and sustained escape attempts 
(swimming and climbing).
43
 Swiss Webster mice were injected (i.p.) with the test compound, vehicle, or 
control antidepressant desipramine, bupropion, or fluoxetine (10-40 mg/kg, i.p.), n=7-10/group. The animals 
were immediately placed in individual locomotor chambers and their total activity was monitored for 30 
minutes. The mice were then individually placed in clear plastic cylinders (height 23 cm, internal diameter 
10 cm) filled with 8 cm of deionized water at 25 °C. Individual mice were videotaped for a total of six 
minutes. Digital video output was then analyzed using the SMART II Video Tracking System Software (San 
Diego Instruments, CA, USA). The software then determined immobility in the six minute session, but only 
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the data of the last four minutes was used to determine the effect. The immobility time was defined as the 
time spent by the mouse moving at a velocity below 2 cm/s. Such a threshold velocity was chosen based on 
previously published data and our validation of the automated system where this threshold produced 
immobility scores similar to those determined from manually scored tapes.
44
 
2.4 Locomotor Activity  
Coupled with the FST, the effect of the test compound on locomotor activity was monitored to avoid 
any false positives resulting from stimulant action, as well as to evaluate any potential sedative action of the 
compound. Locomotor activity was measured using an automated activity monitoring system (San Diego 
Instruments, CA, USA). Mice were acclimated to the testing environment for 30 minutes and then injected 
(i.p.) with the vehicle (10% ethanol), control antidepressant, or test compound. Each mouse was immediately 
placed in a Plexiglas enclosure and locomotor activity monitored for the next 30 minutes. Activity is 
recorded as interruptions of two sets of photo-beams. The data during the last ten minutes of the testing 
period was analyzed. Immediately following the locomotor measurements (equivalent to the 30 minutes pre-
treatment time), the mice were subject to the FST as described above. 
2.5 In Vitro Binding to Serotonin Receptors 
Compounds 4a, 4c, 4d, and 4e were assayed in the NIMH Psychoactive Drug Screening Program 
which provides screening of pharmacological activity in the panel of cloned human and rodent receptors, 
channels, and transporters. For experimental details, please refer to the PDSP web site 
http://pdsp.med.unc.edu. 
2.6. Data Analysis 
All values were presented as mean ± S.E.M. with n= 7-10 animals /group. All data was analyzed 
using One Way ANOVA followed by Dunnett’s post hoc test to determine significant difference from the 
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vehicle control at p<0.05. 
3. Results  
Compounds 3a-e and 4a-e were evaluated for their potential antidepressant activity in the forced 
swim test, (Figures 105A and 106A), which is a reliable and widely used animal model for antidepressant 
screening.
45
 The compounds were initially evaluated at a dose of 20 mg/kg in comparison to the parent 2-
(5,6-di-bromo-1H-indol-3-yl)-N,N-dimethylethanamine and 2-(5-bromo-1H-indol-3-yl)-N,N-
dimethylethanamine derivatives previously showing significant antidepressant and sedative action at such a 
dose. A set of clinically used antidepressants (the tricyclic antidepressant desipramine, the selective serotonin 
reuptake inhibitor fluoxetine, and the dual dopamine and noradrenaline inhibitor bupropion) were used as 
positive controls.  
 
 
A.                                                                                             B. 
 
 
 
 
 
 
 
 
 
 
Figure 105. Effect of compounds 3a-e (20 mg/kg, i.p.) in (A) the forced swim test and (B) locomotor activity. Data presented as 
the mean ± S.E.M. (n=7-10).  Data were analyzed using One Way ANOVA followed by Dunnett’s post-hoc test where *p<0.05 
and ***p<0.001 were statistically different from the vehicle control. 
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Figure 106.  Effect of compounds 4a-e (20 mg/kg, i.p.) in (A) the forced swim test and (B) locomotor activity. Data presented as 
the mean ± S.E.M. (n=7-10). Data were analyzed using One Way ANOVA followed by Dunnett’s post-hoc test where **p<0.01, 
***p<0.001 were statistically different from the vehicle control. 
 
 The effect on locomotor activity was also evaluated to eliminate any non-specific stimulating effect 
and to reveal any possible sedative activity. As shown in Table 9, the control antidepressants showed 
significant dose-dependent reduction in immobility consistent with their established antidepressant action.  
The effect on locomotor activity was different, whereby both desipramine and fluoxetine caused significant 
reduction in activity, while bupropion showed a significant locomotor stimulant effect. As shown in Figure 
105A, the initial evaluation of analogs revealed that compounds 3a and 3d significantly reduced immobility 
in the FST (p<0.001, and p<0.05, respectively) at the tested 20 mg/kg. The compounds did not significantly 
alter locomotor activity at this dose (Figure 105B). Similarly, compounds 4a, 4c, and 4e showed significant 
antidepressant-like action in the FST (p<0.001, p<0.01, and p<0.001, respectively) when administered at the 
20 mg/kg dose (Figure 106A). Compound 4a did not exert a significant effect on locomotor activity, while 
both compounds 4c and 4e had significant hypolocomotive action (p<0.01, and p<0.001, respectively). On 
the other hand, compound 4b did not affect immobility in the FST but significantly reduced locomotor 
activity (p<0.01) as presented in Figure 106B.   
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   Table 9. Effect of control antidepressants on immobility time in mouse forced     
                 swim test and total locomotor activity 
Treatment Immobility (sec) Locomotor 
Vehicle 121 ± 7.3 1618 ±  142 
Bupropion   10 mg/kg 101 ± 10.5 2746 ± 298
*
 
Bupropion   20 mg/kg 80 ± 7.1** 3564 ± 503
***
 
Bupropion    40 mg/kg 58 ± 8.2 *** 5290 ± 544
***
 
Fluoxetine    10 mg/kg 91 ± 10 1898 ± 132 
Fluoxetine    20 mg/kg 90 ± 6.8 1293 ± 243 
Fluoxetine    40 mg/kg 75.8 ± 12.9** 143 ± 34*** 
Desipramine 10 mg/kg 112 ± 6.6 763 ± 112** 
Desipramine 20 mg/kg 81 ± 4.9** 776 ± 265** 
Desipramine 40 mg/kg 70 ± 8.9*** 117 ± 43*** 
                                           *p<0.05, **p<0.01, ***p<0.001 (Dunnett’s post-hoc test versus vehicle) 
 
Full dose response studies for effects in FST, as well as locomotor activity were conducted for 
compounds 3a, 3d, 4a, 4c, 4d, and 4e (Figures 107-112A and 107-112B). Results revealed that, with the 
exception of compound 4d, all the tested compounds show a U-shaped dose response effect in the FST.  
Compound 3a shows only significant antidepressant-like action at the 20 mg/kg dose only (p<0.01) and a 
significant increase in locomotor activity at the 40 mg/kg dose (p<0.01). Compound 4c showed a significant 
reduction in immobility time at the 10 (p<0.01) and 20 (p<.001) mg/kg doses and significant decrease in 
locomotor activity at both the 20 and 40 mg/kg doses (p<0.01). Similarly, compound 4e had significant 
antidepressant-like effect in the FST at 10 and 20 mg/kg (p<0.001) that coincided with a significant 
hypolocomotive effect (p<0.05 at 10 mg/kg and p<0.01 at 20 mg/kg). Although compound 4d did not show 
an antidepressant-like action in the initial evaluation studies, a significant reduction in immobility was 
observed at 40 mg/kg (p<0.001) accompanied by a significant decrease in locomotor activity at the same 
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dose (p<0.01). 
 
       
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 107.  Dose response curves of compound 3a in (A) the forced swim test and (B) locomotor activity. Data presented as the 
mean ± S.E.M. (n=7-10). Data were analyzed using One Way ANOVA followed by Dunnett’s post-hoc test where **p<0.01 was 
statistically different from the vehicle control. 
 
 
 
 
 
 
  
         
         
 
 
 
 
 
 
 
Figure 108.  Dose response curves of compound 3d in (A) the forced swim test and (B) locomotor activity. Data presented as the 
mean ± S.E.M. (n=7-10). Data were analyzed using One Way ANOVA followed by Dunnett’s post-hoc test where *p<0.05 were 
statistically different from the vehicle control. 
 
 
 
A.  
0
10
 
20
 
40
 
0
50
100
150
**
Compound 3a (mg/kg)
Im
m
o
b
ili
ty
 (
s
e
c
)
0 10 20 40
0
500
1000
1500
2000
2500
**
Compound 3a (mg/kg)
L
o
c
o
m
o
to
r 
A
c
ti
v
it
y
B. 
A. 
0
10
 
20
 
40
 
0
50
100
150
*
Compound 3d (mg/kg)
Im
m
o
b
il
it
y
B. 
0 10 20 40
0
500
1000
1500
2000
Compound 3d (mg/kg)
L
o
c
o
m
o
to
r 
A
c
ti
v
it
y
 120 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 109.  Dose response curves of compound 4a in (A) the forced swim test and (B) locomotor activity. Data presented as the 
mean ± S.E.M. (n=7-10). Data were analyzed using One Way ANOVA followed by Dunnett’s post-hoc test where **p<0.01 was 
statistically different from the vehicle control. 
 
 
 
 
 
 
 
 
 
        
         
 
 
 
 
 
 
 
 
 
 
Figure 110.  Dose response curves of compound 4c in (A) the forced swim test and (B) locomotor activity. Data presented as the 
mean ± S.E.M. (n=7-10). Data were analyzed using One Way ANOVA followed by Dunnett’s post-hoc test where **p<0.01 was 
statistically different from the vehicle control.   
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Figure 111.  Dose response curves of compound 4d in (A) the forced swim test and (B) locomotor activity. Data presented as the 
mean ± S.E.M. (n=7-10). Data were analyzed using One Way ANOVA followed by Dunnett’s post-hoc test where **p<0.01 and 
***p<0.001 were statistically different from the vehicle control.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
Figure 112.  Dose response curves of compound 4e in (A) the forced swim test and (B) locomotor activity. Data presented as the 
mean ± S.E.M. (n=7-10). Data were analyzed using One Way ANOVA followed by Dunnett’s post-hoc test where *p<0.05, 
**p<0.01, ***p<0.001 were statistically different from the vehicle control.   
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Compounds 4a, 4c, 4d, and 4e were assayed for their in vitro binding to serotonin 
receptors in the panel of cloned human and rodent receptors, channels, and transporters available 
in the NIMH Psychoactive Drug Screening Program. As shown in Table 10, compounds 4a, 4c, 
4d, and 4e showed high nanomolar affinity to several serotonin receptor subtypes. Highest 
affinity was observed towards 5HT1A, 5HT1B/1D, 5HT2B, 5HT6, and 5HT7 subtypes; (Figures 113-
124). In vitro Vero cell (kidney fibroblast cells) cytotoxicity of 4a, 4c, and 4d was not observed 
up to the maximum dose of 100 μg/mL. 
 
Table 10.  Binding affinities of 4a, 4c, 4d, and 4e towards serotonin receptors 
Receptor Compound 4a 
Ki [nM] 
Compound 4c 
Ki [nM] 
Compound 4d 
Ki [nM] 
Compound 4e 
Ki [nM] 
Controls 
Ergotamine 
Ki [nM] 
Methysergide 
Ki [nM] 
5HT1A 110.0 ± 17.0 5.5 ± 0.4 9.6 ± 1.1 130.0 ± 16.0 0.17 14.0 
5HT1B 66.0 ± 9.0 66.0 ± 5.0 19.0 ± 2.0 43.0 ± 5.0 0.3 2.5 
5HT1D 29.3 ± 3.7 14.0 ± 1.0 2.6 ± 0.32 8.5 ± 1.38 0.3 69.0 
5HT1E >10,000 356.0 ± 34.0 398.0  ± 30.0 310.0 ± 33.0 19.0 237.0 
5HT2B 145.0 ± 13.0 7.8 ± 0.7 27.0 ± 1.0 98.0 ± 4.0 1.9 0.1 
5HT3 5,187 ± 883 1,325 ± 125 1,374 ± 212 4,486 ± 804 >10,000 >10,000 
5HT5A >10,000 408.0 ± 54.0 1,038 ± 110 1,254 ± 197 - >10,000 
5HT6 189.5 ± 32.5 30.0 ± 2.0.0 22.0 ± 2.0 198.0 ± 20.0 12.0 52.0 
5HT7 77.0 ± 16.0 7.2 ± 0.6 8.3 ± 0.9 116.0 ± 13.0 1,291 30.0 
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            Figure 113. In vitro binding affinity of 4a and 4d towards 5-HT1D 
 
 
 
         Figure 114. In vitro binding affinity of 4a and 4d towards 5-HT1E 
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                 Figure 115. In vitro binding affinity of 4a and 4d towards 5-HT3 
 
 
 
 
 
         Figure 116. In vitro binding affinity of 4c towards 5-HT2C 
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         Figure 117. In vitro binding affinity of 4d and 4e towards 5-HT1A 
 
 
 
         Figure 118. In vitro binding affinity of 4d and 4e towards 5-HT1B 
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                        Figure 119. In vitro binding affinity of 4d and 4e towards 5-HT2B 
 
 
 
         Figure 120. In vitro binding affinity of 4d and 4e towards 5-HT5A 
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         Figure 121. In vitro binding affinity of 4d and 4e towards 5-HT6 
 
 
 
         Figure 122. In vitro binding affinity of 4d and 4e towards 5-HT7 
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         Figure 123. In vitro binding affinity of 4d and 4e towards dopamine 2 receptor  
 
 
 
         Figure 124. In vitro binding affinity of 4e towards 5-HT1E 
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4. Discussion 
This study aimed at the synthesis of various derivatives of 2-(1H-indol-3-yl)-N,N-
dimethylethanamine with different halogens at position 5 and evaluation of  their activity both in 
vitro and in vivo for potential antidepressant and sedative actions.   
As shown in Table 9, the tricyclic antidepressant desipramine, the selective serotonin 
reuptake inhibitor fluoxetine, the dual dopamine and noradrenaline inhibitor bupropion, all 
showed dose dependent reduction in immobility times in the FST. Such effects were previously 
established as a measure of antidepressant-like action. Both desipramine and fluoxetine caused 
significant reduction in locomotor activity indicative of their established sedative action. On the 
other hand, bupropion induced a significant stimulant effect. These trends are consistent with 
previously published literature.
46,47
      
Compound 3a exhibited significant (p<0.001) antidepressant-like activity in the FST at 
20 mg/kg dose (Figure 105A). Similarly, compound 3d caused significant (p<0.05) reduction in 
immobility, which is indicative of antidepressant action. Furthermore, such effect was not 
associated with any effect on the locomotor activity of the animals, as shown in Figure 105B. 
Such data indicates possible antidepressant action for both compounds without any possible 
sedative effect at the tested dose. Figure 106 shows the effect of compounds 4a-e in the FST 
(Figure 106A) and on the locomotor activity of animals in an open field (Figure 106B). 
Compound 4a; N,N-dimethyltryptamine (DMT) is a known hallucinogen found in psychoactive 
snuffs and teas used by native shamans of South America. DMT is also produced in mammalian 
organisms, and it was recently reported to be an endogenous sigma receptor ligand.
48
 In our 
study, compound 4a caused significant reduction in immobility (p<0.001) in the FST and a non-
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significant reduction in locomotor activity. The compound did not cause any locomotor stimulant 
action usually associated with hallucinogenic effects at any of the tested doses. Compounds 4c 
and 4e exhibited significant antidepressant-like action in the FST (p<0.01, and p<0.001, 
respectively) at the 20 mg/kg dose. In addition, compounds 4b, 4c, and 4e caused significant 
reduction in locomotor activity, suggesting potential sedative effect.     
Full dose response studies for compound 3a elicited U-shaped dose response 
antidepressant-like action (Figure 107A) with the 20 mg/kg dose significantly different from the 
vehicle control (p<0.01). A similar U-shaped response was observed in locomotor activity with a 
significant stimulant action evident at the 40 mg/kg dose (p<0.01). All tested compounds except 
compound 3d exhibited such U-shaped antidepressant-like dose response curve (Figures 107, 
109-112). In some cases, the lack of antidepressant action at the high dose can be partially 
explained by the severe sedative action observed in the locomotor activity (compound 4c, Figure 
110B). Such severe sedation can mask the antidepressant action by hindering the animal’s ability 
to escape or move. Further studies are needed to examine the potential sedative action of this 
compound. In other cases (compounds 4a and 4e), the trend of the effect on locomotor activity 
does not correlate with the lack of antidepressant action (Figures 109 and 112). The observed U-
shaped dose response could possibly be attributed to activation of a separate set of pathways 
through the action on multiple receptors at the high dose. Thus mechanistic studies are warranted 
to delineate the mechanisms underlying the observed antidepressant and sedative actions for 
these compounds. On the other hand, compound 3d showed a typical dose dependent response 
curve with significant antidepressant-like action at the 40 mg/kg dose (p<0.01) and no 
significant effect on locomotor activity (Figure 108).  
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In vitro binding affinities data showed that compounds 4a, 4c, 4d, and 4e possessed 
nanomolar affinity to several serotonin receptor subtypes, particularly 5HT1A, 5HT1B/1D, 5HT2B, 
5HT6, and 5HT7 subtypes. Previous research suggested the involvement of these serotonin 
receptor subtypes in depression, anxiety, and migraines.
49
 The utilization of 5HT1A knockout 
animals resulted in enhanced anxiety in several experimental paradigms as well as demonstrated 
significant increased baseline immobility in behavioral despair tests.
50,51
 Moreover, selective 
5HT1A agonists showed antidepressant actions in preclinical as well as clinical testing.
52-55
 The 
involvement of 5HT1B receptors in mood disorders was also observed in knockout models. Such 
mice exhibited a decreased anxiety in open field, elevated plus maze, and tail suspension tests. 
On the other hand, the same mice displayed increased aggressive behavior.
56,57
 Additionally 
5HT1B and 5HT1D receptors are well known targets for antimigraine drugs. A number of studies 
examined the role of 5HT2B receptors in mood regulation. These studies showed that direct 
injection of the selective 5HT2B agonist, BW 723C86, into the medial amygdale resulted in 
anxiolytic effect in the rat social interaction test.
58
 Recently, the attribution of 5HT6 and 5HT7 
receptors in neuropsychiatric disorders drawn attention due to the pharmacological studies that 
demonstrated high affinity of several antipsychotic and antidepressant agents to these two 
receptor subtypes.
59,60
 Thus the in vitro data suggested that the antidepressant action exerted by 
these compounds in vivo might be mediated via interaction with serotonin receptors. Further 
mechanistic studies are hence required to delineate the nature of such interaction and further 
establish the mechanism underlying the observed behavioral effects of these compounds. 
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CHAPTER V 
 
2-N- MODIFICATIONS AND SAR STUDIES OF MANZAMINE A  
Published in Bioorganic & Medicinal Chemistry 2008, 16, 6702-6706. 
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1. Introduction 
Malaria, a major tropical infectious disease caused primarily by the protozoan parasite 
Plasmodium falciparum, is one of the most serious health problems worldwide and is responsible 
for the death of over 1.12 million individuals every year with more than 40 percent of the global 
population at risk.
61
 -Carboline alkaloids are widely distributed in a number of plant and animal 
species, as well as marine invertebrates. Some of these alkaloids such as manzamine A (1), 
akagerine, 10-hydroxycanthin-6-one and 4-methoxy-1-vinyl--carboline (MVC) (Figure 125), 
display a diverse array of biological activities including antiplasmodial efficacy.
62-64
 Manzamine 
A, as a first representative of the manzamine alkaloids, bearing a unique multi-heterocyclic ring 
system coupled to a β-carboline moiety, was isolated from the sponge Haliclona sp. collected 
near Manzamo Island by Higa and co-workers in 1986.
65 
Despite its potent in vitro activity as an 
antimalarial agent against P. falciparum the toxicity of manzamine A hampered its development 
as a drug candidate.
64, 66-68
  
Recently, Ihara and co-workers have reported that the rhodacyanine family of compounds 
and the -carboline system of MVC, owing in both cases to a π-delocalized lipophilic cationic 
(DLC) structure, display reasonable antimalarial and antileishmanial activities against P. 
falciparum and Leishmania major, respectively, with low cytotoxicity against mammalian 
cells.
69-73
 The conceptual term, DLC, was originally proposed by Chen et al. in their studies 
related to anticancer agents.
74
 It has been reported that several DLC compounds exhibit selective 
antitumor activity by accumulating in the mitochondria of carcinoma cells.
75-77
 Vaidya and co-
workers found that mitochondrial membrane potential collapse is an antimalarial mechanism of 
some drugs,
78
 and many researchers concluded that DLCs could therefore represent a new 
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antiplasmodial class of drugs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                   
       
  
    
 
    Figure 125. -Carboline alkaloids with potential biological activities 
 
 
Our goal was to synthesize manzamine A analogs with decreased toxicity and improved 
therapeutic index for antimalarial efficacy and continuing structure-activity relationship studies. 
The rationale for the modification of the -carboline moiety through quarternization of the 
pyridine nitrogen to form -carbolinium salts is based on previous work that showed reduced 
toxicity and increased antimalarial activity of DLC’s formed upon transformation with either 
alkyl tosylates or alkyl halides as a correlation to the π–delocalization of the cationic 
species.
70,71,79 
Recently, we found that manzamine A inhibits GSK-3β with an IC50 value of 10.2 µM so 
inhibition of this multifunctional serine/threonine kinase may in part be the reason for various 
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therapeutic activities of manzamine A analogs.
80
 Since, the crystal structure of GSK-3β is 
available, we initiated structure-based drug design paradigm of manzamine A analogs using 
molecular docking coupled with molecular dynamics. Quaternization of the neutral pyridine 
nitrogen to the desired quaternary ammonium cation was challenging but could finally be 
accomplished by methylation of manzamine A in the presence of methyl 
trifluoromethanesulfonate to afford three methylated products (2-4) in varying yields depending 
upon reaction conditions. The structures of 2, 3, and 4 were confirmed using HRESIMS, as well 
as 
1
H, 
13
C NMR, HMQC, and HMBC data. The in vitro antimalarial and antimicrobial activity in 
addition to cytotoxicity versus mammalian cells of analogs 2-4 were evaluated.      
2-N-Methylmanzamine A (2), 2-N,12-O-dimethyl manzamine A (3) 
trifluoromethanesulfonate, and 9-N-methylmanzamine A (4)  (Scheme 8)  are generated from the 
treatment of the -carboline moiety with methyl trifluoromethanesulfonate to afford the mono- 
and di-methylated products.
71,79
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Scheme 8. Synthesis of 2-N-methylmanzamine A (2), 2-N,12-O-dimethylmanzamine A (3)  
                                 trifluoromethanesulfonate, and 9-N-methylmanzamine A (4) 
 
 
According to our previous unpublished work showing that N-methylation of the 
secondary amine of the -carboline moiety drastically decreases antimalarial potency, along with 
the low yield of 4, we were not interested to pursue further evaluation of this compound. Using 
methyl iodide as the alkylating agent furnished the non-preferential analogue 4 in higher yield.  
The structures of analogues 2 and 3 were confirmed with spectroscopic and MS 
techniques. The (+)-HRESIMS of analog 2 showed the [M+H]
+
 ion signal with m/z 563.36747 in 
positive mode, in accordance with its molecular formula C37H47N4O. The 
1
H NMR spectrum of 3 
in methanol-d4 in 400 MHz clearly indicated the presence of a new singlet methyl group at 4.57 
(s, 3H, NCH3) ppm. This finding was confirmed by a new methyl singlet at 45.3 ppm in the 
13
C 
NMR spectrum. The HMBC spectrum of 2 supported the methylation of the pyridinium nitrogen 
as shown by a correlation between the CH3 singlet at 4.57 ppm and both adjacent aromatic 
carbon signals at 134.6 ppm (C-3) and 138.8 ppm (C-1) (Figure 126). 
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Figure 126.  Selected HMBC correlations 2-N-methylmanzamine A (2), and 2-N,12-O-dimethylmanzamine A (3)  
trifluoromethanesulfonate 
 
 
High-resolution TOF-ESIMS of analog 3 provided a molecular mass of [M+H]
+
 with m/z 
577.4245, corresponding to the addition of two methyl mass units, in comparison with the parent 
molecule. The 
1
H and 
13
C NMR spectra of compound 3 in DMSO-d6 contained two methyl 
proton signals at 4.41 (s, 3H, NCH3) and 3.13 ppm (s, 3H, OCH3) along with corresponding 
carbon resonances at 45.9 and 54.1 ppm, respectively, in agreement with the structure of analog 
3 (Figure 126). In addition, HMBC spectrum revealed an unambiguous correlation between the 
methoxy protons at 3.13 ppm and neighboring quaternary C-12 at 62.1 ppm. These findings are 
consistent with the fact that we observed the NH group at position 9 of the -carboline moiety 
still intact at 11.4 (s, 1H, NH), which in turn indicates that secondary amine group is not 
involved in the methylation. 
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2. Biological Evaluation 
All synthetic analogues were evaluated for in vitro antimalarial and antimicrobial activity 
as well as cytotoxicity against mammalian cells.  
Antimalarial activity was determined against chloroquine-sensitive (D6) and chloroquine-
resistant (W2) strains of P. falciparum. As shown in Table 11, compound 2 showed antimalarial 
activity with IC50 values of 0.7 and 1.0 µM for D6 and W2 strains, respectively. Compounds 3 
and 4 were inactive. None of the synthesized analogs (2-4) showed any cytotoxicity to 
mammalian kidney fibroblasts (Vero cells) while manzamine A was cytotoxic (IC50 0.5 µM). 
Although antimalarial activity of 2 was much less potent than manzamine A, the selectivity 
index of 2 remained comparable to manzamine A due to the loss of cytotoxicity. These results 
indicated that quarternization of the β-carboline moiety resulted in reduced toxicity but still 
retained antimalarial efficacy in the case of 2. However, further methylation of 2 (to generate 3) 
resulted in loss of antimalarial activity. Methylation of the indoline nitrogen of manzamine A (4) 
resulted in the loss of both antimalarial activity and cytotoxicity. 
Manzamine A and some of its analogs are known to inhibit Homo sapiens glycogen 
synthase kinase-3β (GSK-3β).80 Based on the assumption that the antimalarial activity of these 
analogs may be due to kinase inhibition of P. falciparum, we used the crystal structure of 
HsGSK-3β (PDB: 1gng)81 for docking studies to predict the optimal binding positions and 
relative binding propensities of 1-3. Based on the evidence that 1 was found to be an ATP-
noncompetitive inhibitor of GSK-3β,80 we attempted to dock 1-3 into a pocket located in the 
vicinity of the activation pocket formed by three basic residues, Arg96, Arg180 and Lys205. We 
used the GOLD 3.1.1 docking program
82
 with the scoring function ChemScore,
83
 to compare the 
 139 
difference in binding affinity between the ligands and to compare with the experimental in vitro 
antimalarial activity. The co-crystallized ligands in 1gng, namely 2-amino-2-hydroxymethyl-
propane-1,3-diol and sulfate ions, were removed before docking. The active site was defined as 
any atom that lay within a 15 Å radius of the δN of Arg96. The geometry of 1 was optimized 
using MMFF94 in Sybyl 7.2, starting from the published X-ray crystal structure of manzamine 
A.
65 
2 and 3 were built from the crystal structure of 1 followed by geometry optimization using 
the same force field. ChemScore is a dimensionless fitness function which is a measure of the 
free energy of a ligand binding to a protein. Since GOLD uses a genetic algorithm to dock 
ligands, consecutive docking runs do not give exactly the same fitness scores. To address this 
issue of inherent randomness of GOLD docking, we performed 3 consecutive docking runs to 
obtain average ChemScores for each ligand, which are given in Table 11 for 1-3.  
 
Table 11. In vitro antimalarial activity, selectivity index, cytotoxicity to Vero cells and docking scores 
of manzamine A (1), 2-N-methylmanzamine A (2), 2-N,12-O-dimethylmanzamine A (3) 
trifluoromethanesulfonate, and 9-N-methylmanzamine A (4)  
Compound 
P. falciparum D6 P. falciparum W2 Cytotoxicity to Vero cells Docking Score 
IC50 (µM) S.I. IC50 (µM) S.I. IC50 (µM) ChemScore
a 
1 0.017 29.4 0.020 25.23 0.501 24.9 (±1.0) 
2 0.736 >24 1.011 >17.5 NC 22.3 (±0.6) 
3 NA – NA – NC 20.6 (±0.8) 
4 NA – NA – NC – 
Chloroquine 0.013 >1000 0.135 >100 NC – 
Artemisinin 0.0063 >2700 0.0045 >3700 NC – 
 
NA= No antimalarial activity up to 8 µM; NC = No cytotoxicity up to 17 µM:  Selectivity Index (S.I.) = IC50 (Vero 
Cells) / IC50 (P. falciparum). 
aGOLD ChemScore was an average over 3 runs. Standard deviation in parentheses.  
 
Docking scores agree with the in vitro antimalarial activity data and show that 1 > 2 > 3. 
This is consistent with the experimental findings that the first methylation on the tertiary nitrogen 
of the β-carboline ring (2) and the second methylation on the 12-hydroxy group (3) each 
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decrease the antimalarial activity a step compared to having free tertiary nitrogen on the β-
carboline ring and a 12-hydroxy group in manzamine A (1) (Table 11). 
The predicted binding positions of 1-3 within the ATP-noncompetitive binding pocket (as 
identified by the Lee and Richards solvent accessible molecular surface)
84
 are shown in Figure 
127.  
Compounds 1 and 3 have the same binding mode, whereas the binding position of 2 is 
different. The polar and hydrophobic interactions of 1 are shown in Figure 128. Manzamine A 
(1) shows a strong hydrogen bonding of its 12-hydroxy group with the backbone carbonyl of 
Arg92. Also, the hydrophobic β-carboline ring interacts with the side chains of Lys94, Asn95 
and Arg96. The NH of the β-carboline ring is pointing towards Phe93 indicating a probable steric 
clash if any substitution is made at this position. In comparison to 1, 2 adopts a binding mode in 
a different region of the ATP-noncompetitive binding pocket, leading to less favorable hydrogen 
bonding and hydrophobic interactions. The crucial interactions for 2 are also shown in Figure 
128. The 12-hydroxy group of 2 forms a hydrogen bond, but it is with Gln89, unlike that of 1 
with Arg92. The hydrogen bonding between the NH2 of Gln89 and the 12-hydroxy of 2 is 
weaker (more distant) than the interaction seen in 1. Also, 2 shows hydrophobic interactions with 
the side chain of Phe67. 3 adopts a binding position similar to 1, and 3 does not show any 
hydrogen bonding interaction, due to the second methylation at the 12-hydroxy group. Thus the 
docking scores are in good agreement with the antimalarial results indicating their utility in the 
rational design of more active analogs from this class.  
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Figure 127. Binding positions of manzamine A (1), 2-N-methylmanzamine A (2), and 2-N,12-O-dimethylmanzamine A 
(3) trifluoromethanesulfonate within the ATP-noncompetitive binding pocket of GSK-3β (A: 1, B: 2, C: 3). Ligands 1-3 are 
shown with green carbon; the protein is in ribbon format colored according to secondary structures; the binding pocket interior 
surface (as detected with the Lee/Richards molecular surface) is in white.  
 
 
 
Figure 128. Interactions of manzamine A (A) and 2-N-methylmanzamine A trifluoromethanesulfonate (B) with the 
GSK-3β ATP-noncompetitive binding pocket residues. 
 
 
Antimicrobial activity was determined against a panel of human pathogenic bacteria and 
fungi (Table 12). Compounds 1 to 4 were inactive against the Gram-negative bacteria 
Escherichia coli and Pseudomonas aeruginosa, in addition to the opportunistic filamentous 
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fungus Aspergillus fumigatus (data not shown). Moreover, compound 4 was inactive against all 
species tested, indicating that quaternarization of the secondary amine decreases bioactivity in 
general. Among compounds 1-3, manzamine A (1) remains the most potent with strong activity 
against the opportunistic yeast Cryptococcus neoformans, methicillin-resistant Staphylococcus 
aureus (MRSA) and Mycobacterium intracellulare, with bioactivity against the latter 
microorganism rivaling the positive control Ciprofloxacin. Results indicated that the conversion 
of hydroxyl group to a methoxy in compound 3 also decreases in vitro antimicrobial activity. In 
summary, derivatization of either the pyridine or secondary amine of the β-carboline moiety, 
along with methylation of the C-12 hydroxy group of manzamine A decrease in vitro activity 
against several pathogenic microorganisms. Also anti-HCV activity for compound 2 was 
evaluated (Table 13). 
 
Table 12. In vitro antimicrobial activity for manzamine A (1), 2-N-methylmanzamine A (2), 2-N,12-O-
dimethylmanzamine A (3) trifluoromethanesulfonate, and 9-N-methylmanzamine A (4), (all values in 
µM) 
Compound 
C. albicans C. neoformans MRSA M. intracellulare 
IC50 MIC MFC IC50 MIC MFC IC50 MIC MBC IC50 MIC MBC 
1 16.4 - - 2.7 5.7 23 0.18 - - 0.18 0.36 2.84 
2 - - - 71.1 - - 44.5 89 89 17.8 44.5 44.5 
3 - - - 52 87 87 - - - - - - 
4 - - - - - - - - - - - - 
Amphotericin B 0.3 0.68 1.35 0.8 1.35 1.35 NT NT NT NT NT NT 
Ciprofloxacin NT NT NT NT NT NT 0.3 1.5 - 1.1 1.5 3 
 
IC50, the concentration that affords 50% inhibition of growth; minimum inhibitory concentration (MIC) is the lowest test 
concentration that allows no detectable growth; minimum fungicidal/bactericidal concentration (MFC/MBC) is the lowest test 
concentration that kills the organism  
“-“, not active at the highest test concentration of 91, 89, 87, 89, 5.4 and 3.0 for samples 1, 2, 3, 4, Amphotericin B, and 
Ciprofloxacin, respectively; NT, not tested. 
Amphotericin B and ciprofloxacin are used as positive antifungal and antibacterial controls, respectively. 
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       Table 13. Anti-HCV activity of 2-N-methylmanzamine A trifluoromethanesulfonate (2) in the Huh-7 
replicon assay 
 
 
 
 
2'-C-methylcytidine; a RS-446 (2′-C-Me-C) was used as the control. The compound and the control are tested at 10 µM in 
triplicate immediately after seeding. 
 
 
In conclusion, the preliminary structure–activity relationship study in regards to the first 
and second methylation showed that the introduction of the first methyl group at the pyridine 
nitrogen in the β-carboline moiety of manzamine A significantly decreases the cytotoxicity but 
also reduced the antimalarial activity of manzamine A. Introduction of a second methyl group at 
12-OH completely eliminated the antimalarial activity indicating that the OH group is an 
essential pharmacophore for the antimalarial activity of the manzamine class of alkaloids. The 
docking studies of these analogs on GSK-3β delineated the ability of manzamine A (1) to form a 
stronger hydrogen bond than 2 and the inability of 3 to interact favorably with the ATP-
noncompetitive site amino acids of GSK-3β, because 3 lacks a complementary donor atom at its 
C-12-OH position. 
3. Experimental Section 
3.1. General Preparation of Compounds 3-4.  
Treatment of manzamine A (54.8 mg, 0.1 mmol) with methyl trifluoromethanesulfonate 
(135.5 µL, 1.2 mmol) in a molar ratio of 1 to 1.2 in dry methylene chloride while stirring for 48 
h at ambient temperature resulted in the formation of major product 2 in 70% yield in addition to 
two minor products 3 in 15%, and 4 in 3% yield. Purification was completed via HPLC using a 
reverse-phase C8 column with a mobile phase gradient of H2O-CH3CN and a flow rate of 10 
Compounds ΔCt HCV ΔCt  rRNA 
% Inhibition 
HCV rRNA 
2 9.56 15.74 99.87 100.00 
RS-446
a
 7.48 -0.25 99.43 -19.22 
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mL/min. The major compound appears at a retention time of 40 minutes.  
By increasing the molar ratio of methyl trifluoromethanesulfonate from 1.2 to 2.4 and 
stirring for 72 h, compound 3 was generated in 65% yield alongside the minor products 2 in 
20%, and 4 in 5% yield. The resultant yellow solid was washed with diethyl ether and purified 
using the method above affording compound 3 at a retention time of 30 minutes. 
3.1.1. 2-N-Methylmanzamine A trifluoromethanesulfonate (2); (Figures 129-136) 
[α]25D +57.5 (c = 0.08, MeOH); UV λmax (MeOH) 260, 310, 375 nm; IR max (CHCl3) 
3207 (NH), 3073, 3011, 2928, 2855, 1671, 1628, 1577, 1520, 1415, 1296, 1198, 1030 cm
-1
; 
1
H 
NMR (methanol-d4) δ 8.65 (2H, m), 8.43 (1H, d), 7.87 (2H, m), 7.52 (1H, t), 6.27 (1H, s), 5.68 
(2H, m), 5.53 (1H, t), 4.71 (1H, m), 4.57 (3H, s, NCH3), 4.43 (1H, m), 3.89 (1H, s), 3.65 (1H, 
m), 3.48 (1H, t) and 3.35-0.90 (complex); 
13
C NMR (methanol-d4)  δ 144.8, 141.8, 138.8, 135.4, 
135.2, 134.6, 132.6, 132.2, 132.0, 126.9, 122.7,122.1, 119.9, 116.3, 113.1, 74.8, 69.7, 68.7, 66.6, 
56.9, 53.1, 48.7, 48.4, 46.8, 45.3, 43.2, 40.1, 39.7, 33.0, 28.4, 26.4, 25.4, 24.9, 24.3 and 20.8; 
(+)-HRESIMS m/z calcd for C37H47N4O [M+H]
+
 563.3750, found 563.3674.  
3.1.2. 2-N,12-O-Dimethylmanzamine A trifluoromethanesulfonate (3); (Figures 137-141) 
[α]25D +25.7 (c = 0.14, MeOH); UV λmax (MeOH) 225, 260, 314, 380 nm; IR max 
(CHCl3) 3443 (NH), 3331, 3258, 2981, 2935, 1679, 1606, 1527, 1457, 1391, 1365, 1250, 1157, 
1051 cm
-1
; 
1
H NMR (DMSO-d6) δ 11.40 (1H, s, NH), 8.84 (2H, m), 8.48 (1H, d), 8.23 (1H, d), 
7.72 (1H, t), 7.42 (1H, t), 5.88 (1H, s), 5.52 (1H, m), 5.40 (2H, m), 5.22(1H, m), 4.41 (3H, s, 
NCH3), 4.01 (2H, m), 3.81 (1H, d), 3.56 (2H, m), 3.32 (5H, m), 3.20 (2H, m), 3.13 (3H, s, 
OCH3), 2.89 (3H, m), 2.74 (1H, m) and 1.43-2.19 (complex); 
13
C NMR (DMSO-d6) δ 145.4, 
145.1, 141.8, 138.8, 137.2, 136.1, 135.3, 133.4, 131.9, 129.6, 129.3, 125.8, 123.6, 121.9, 119.8, 
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117.2, 114.6, 74.1, 62.9, 62.1, 61.5, 59.1, 58.2, 54.1, 50.4, 45.9, 45.0, 43.8, 43.0, 36.7, 27.6, 26.4, 
25.8, 25.4, 25.0, 24.2, 23.2 and 18.7; (+)-HRESIMS m/z calcd for C38H49N4O [M+H]
+
 577.3906, 
found 577.4245.  
3.1.3. 9-N-Methylmanzamine A (4); (Figures 142-145) 
 [α]25D +18.6 (c = 0.07, MeOH); UV λmax (MeOH) 260, 310, 375 nm; IR max (CHCl3) 
3648 (NH), 3294, 3011, 2924, 2838, 1675, 1628, 1519, 1443, 1329, 1199, 1017 cm
-1
; 
1
H NMR 
(methanol-d4) δ 8.63, (1H, br s), 8.40 (1H, d), 7.78 (1H, d), 7.53 (1H, d), 7.40 (1H, dd), 6.40 (1H, 
s), 5.91 (1H, br s), 5.62 (1H, q), 5.52 (1H, td), 5.26 (1H, t), 4.31 (1H, br s), 3.92 (3H, s, NCH3), 
3.50 (1H, d), 3.08 (2H, m), 2.78 (1H, m), 2.56 (2H, m), and 1.2-2.5 (complex); 
13
C NMR 
(methanol-d4) λ 154.2, 143.5, 139.9, 138.2, 137.4, 135.1, 134.5, 134.2, 132.3, 129.9, 129.2, 
128.5, 122.2, 118.3, 117.2, 113.3, 112.5, 103.5, 75.1, 70.0, 68.7, 56.0, 55.0, 53.5, 50.9, 49.6, 
47.1, 44.7, 40.9, 40.3, 32.7, 31.7, 28.1, 26.8, 26.0, 25.7, and 21.7; (+)-HRESIMS m/z calcd for 
C37H47N4O [M+H]
+
 563.3750, found 563.3764. 
 146 
 
          Figure 129. Purification of 2-N-methylmanzamine A trifluoromethanesulfonate 2 on 
250 x 21.20 C18 column 
 
 
  
 
            Figure 130. LC/MS chromatogram of 2-N-methylmanzamine A 
trifluoromethanesulfonate 2 
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                  Figure 131. UV spectrum of 2-N-methylmanzamine A trifluoromethanesulfonate 2 
 
 
 
 
 
 
          Figure 132. IR spectrum of 2-N-methylmanzamine A trifluoromethanesulfonate 2 
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                    Figure 133. 
1
H NMR spectrum of 2-N-methylmanzamine A trifluoromethanesulfonate 2 
in methanol-d4 (400 MHz); A) the full spectrum, B) the downfield region 
 149 
 
 
 
 
 
 
          Figure 134. 
13
C NMR spectrum of 2-N-methylmanzamine A trifluoromethanesulfonate 
2 in methanol-d4 (400 MHz); A) the full spectrum, B) the upfield 
region 
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          Figure 135. HMQC spectrum of 2-N-methylmanzamine A trifluoromethanesulfonate 
2 in methanol-d4 (400 MHz); A) the full spectrum, B) the downfield 
region 
 151 
 
 
 
 
 
          Figure 136. HMBC spectrum of 2-N-methylmanzamine A trifluoromethanesulfonate 2 
in methanol-d4 (400 MHz) 
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          Figure 137. LC/MS chromatogram of 2-N,12-O-dimethylmanzamine A (3)    
trifluoromethanesulfonate 
 
 
 
 
          Figure 138. UV spectrum of 2-N,12-O-dimethylmanzamine A (3)  
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trifluoromethanesulfonate 
 
          Figure 139. IR spectrum of 2-N,12-O-dimethylmanzamine A (3)  
trifluoromethanesulfonate 
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          Figure 140. 
1
H NMR spectrum of 2-N,12-O-dimethylmanzamine A (3)  
trifluoromethanesulfonate in methanol-d4 (400 MHz); A) the full 
spectrum, B) the downfield region 
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          Figure 141. 
13
C NMR spectrum of 2-N,12-O-dimethylmanzamine A (3)  
trifluoromethanesulfonate in methanol-d4 (400 MHz); A) the full 
spectrum, B) the upfield region 
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          Figure 142. 
1
H NMR spectrum of 9-N-methylmanzamine A (4) in methanol-d4 (400 
MHz); A) the full spectrum, B) the downfield region 
 157 
 
 
 
          Figure 143. 
13
C NMR spectrum of 9-N-methylmanzamine A (4) in methanol-d4 (400 
MHz); A) the full spectrum, B) the upfield region 
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3.2. Assay for in Vitro Antimalarial Activity and Cytotoxicity 
 A 200 µL suspension of red blood cells infected with D6 or W2 strain of P. falciparum 
(2% parasitemia and 2% hematocrit in RPMI 1640 medium supplemented with 10% human 
serum and 60 µg/mL Amikacin) was added to the wells of a 96-well plate containing 10 μL of 
serially diluted samples. The plate was flushed with a gas mixture of 90% N2, 5% O2, and 5% 
CO2 and incubated at 37 ºC, for 72 h in a modular incubation chamber (Billups-Rothenberg, 
CA). Parasitic LDH activity was determined by using Malstat
TM
 reagent (Flow Inc., Portland, 
OR) according to the procedure of Makler and Hinrichs.
85
 The incubation mixture (20 μL) was 
mixed with 100 μL of the MalstatTM reagent and incubated at room temperature for 30 min 
followed by addition of 20 µL of a 1:1 mixture of NBT/PES (Sigma, St. Louis, MO) and further 
incubation in the dark for 1 hr. The reaction was stopped by the addition of 100 μL of 5% aq. 
acetic acid. The plate was read at 650 nm. Artemisinin and chloroquine were included as the 
drug controls. IC50 values were computed from the dose response curves to determine the 
selectivity index of antimalarial activity of the compounds. The in vitro cytotoxicity to 
mammalian cells was also determined. The assay was performed as described earlier.
86
 Vero 
cells (monkey kidney fibroblasts) were seeded to the wells of 96-well plate at a density of 25,000 
cells/well and incubated for 24 h. Samples at different concentrations were added and plates 
were again incubated for 48 h. The number of viable cells was determined by Neutral Red assay. 
IC50 values were obtained from dose response curves. Doxorubicin was used as a positive 
control. 
3.3. Assay for Antimicrobial Activity   
All organisms are obtained from the American Type Culture Collection (Manassas, VA) 
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and include the fungi Candida albicans ATCC 90028, Cryptococcus neoformans ATCC 90113, 
and Aspergillus fumigatus ATCC 90906 and the bacteria methicillin-resistant Staphylococcus 
aureus ATCC 43300 (MRS), Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 
27853, and Mycobacterium intracellulare ATCC 23068. Susceptibility testing is performed 
using a modified version of the CLSI (formerly NCCLS) methods.
87-90
 M. intracellulare is tested 
using a modified method of Franzblau et al.
91
 Samples are serially-diluted in 20% DMSO/saline 
and transferred in duplicate to 96 well flat bottom microplates. Microbial inocula are prepared by 
correcting the OD630 of microbe suspensions in incubation broth to afford final target inocula. 
Drug controls [ciprofloxacin (ICN Biomedicals, Ohio) for bacteria and amphotericin B (ICN 
Biomedicals, Ohio) for fungi] are included in each assay. All organisms are read at either 630 nm 
using the EL-340 Biokinetics Reader (Bio-Tek Instruments, Vermont) or 544ex/590em, (M. 
intracellulare, A. fumigatus) using the Polarstar Galaxy Plate Reader (BMG LabTechnologies, 
Germany) prior to and after incubation. Minimum fungicidal or bactericidal concentrations are 
determined by removing 5 µL from each clear well, transferring to agar and incubating. The 
MFC/MBC is defined as the lowest test concentration that kills the organism (allows no growth 
on agar). 
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CHAPTER VI 
 
HCV LEADS FROM THE SOUTH AMERICA ENDANGERED PLANT DIPLOSTEPHIUM 
RHODODENDROIDES  
 
 
 
  World distribution of Diplostephium rhododendroides and hepatitis C carriers 
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Although plants and marine organisms represent crucial sources in the field of drug 
discovery, little attention has been given to endangered and rare plant species. However, 
threatened plant species may provide drug leads for serious diseases that kill a large number of 
the population each year and if these opportunities are missed they may be gone forever. In 2009, 
the UK-Plantlife reported that about 15,000 of the 50,000 wild medicinal plants are at risk and 
headed for extinction.
92
 Gilbert et al. reported in 2010 that more than 17,000 species of fauna and 
flora were at risk of extinction in 2009 and over half of all medicinal plants in Africa face 
extinction.
93
 This causes serious concern, as the World Health Organization estimates that 80% 
of the world’s population relies on traditional plant derived medicines for their pharmacopeia. 
The U.S. Fish & Wildlife Service declared that 795 plant species are at risk of extinction 
throughout the United States. According to Gordon Cragg, former director of the natural 
products branch of the NCI, over 60% of cancer therapeutics were derived from naturally-
occurring products.
94
 Various examples have been reported, like extracts from Catharanthus 
roseus (Rosy periwinkle) used to treat Hodgkin's disease and leukemia,
95
 digitalis from Digitalis 
purpurea (foxglove) for the treatment of heart disease,
96
 galantamine from Galanthus caucasicus 
(snowdrops) used for the treatment of Alzheimer's disease
97
 and paclitaxel, the anti-cancer drug 
Taxol
TM
, from the bark of the Pacific yew tree.
98
 Though habitat loss and climate change
99
 are 
the primary cause of species endangerment, other biological factors such as competition and 
invasion;
100
 non-native fungi,
101
 viruses or exotic arthropods,
102
 can also drive plant species to 
extinction. For example, the Florida torreya (Torreya taxifolia) suffered a tragic decline due 
primarily to the fungus Pestalotiopsis microspora residing in its inner bark, triggering 
pathogenic activity on the host.
103
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Is it possible that rare plants can provide promising HCV treatments similar to the anti-
cancer drug, Taxol? 
Hepatitis epidemics were first recorded as early as 2000 B.C. but it wasn’t until 1989 that 
hepatitis C virus (HCV) was identified
104
 in tissue samples of chimpanzees.
105
  
As many as four million individuals in the United States and 200-300 million worldwide 
are infected with HCV.
106
 According to the CDC, there were up to 18,000 new HCV infections 
in the United States in 2008 and HCV is responsible for 12,000 deaths annually. According to 
The Hepatitis Central, HCV accounts for 20% of acute hepatitis cases, 70% of chronic hepatitis, 
40% of end-stage cirrhosis, 60% of hepatocellular carcinoma, and 30-40% of liver transplants. 
The CDC estimates that in the next two decades, chronic HCV will be a major burden on the 
health care system. The direct medical costs of chronic HCV infection are estimated to exceed 
$10.7 billion, $54.2 billion for the societal cost of premature mortality, and $21.3 billion for the 
cost of disability due to HCV infections.
 
According to Hepatitis Central statistics, there will be a 
60% increase in the incidence of cirrhosis, a 68% increase in hepatoma incidence, a 279% 
increment in the incidence of hepatic decompensation, a 528% increase in the need for 
transplantation, and a 223% increase in liver death rates from HCV in the next 10-20 years.  
HCV is a spherical, enveloped, single-stranded RNA virus (family Flaviviridae) that can 
replicate in the trillions at steady state.
107
 The RNA-dependent RNA polymerase generates a 
large number of mutant viruses known as quasi-species, presenting a major challenge in the 
control of HCV.
108
 Of the six major HCV genotypes, genotype 1 is the most common in the 
United States. Genotype 1 is associated with more severe liver diseases and a higher risk of 
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hepatocellular carcinoma.
109
 The classified genotype 1b does not respond to therapy as well as 
genotypes 2 and 3.
109
 Genotype 4 is the most prevalent genotype in Egypt, while genotype 5 is 
found in South Africa and genotype 6 in Southeast Asia. HCV encodes a single polyprotein of 
3011 amino acids that is processed into 10 structural and regulatory proteins (Figure 144). This 
includes the core and two envelope proteins, E1 and E2 with a high rate of mutation.
110
 
 
  Figure 144. HCV genome and polyprotein potential drug target 
 
 
According to Murray and Rice,
111
 HCV replicates using a series of enzymes, including 
the two proteases (NS2-3 and NS3-4A), a helicase (NS3), and a polymerase (NS5B) (Figue 145). 
Of these, NS3-4A and NS5B have attracted the most attention as drug targets. In 2010, Gao et al. 
reported a potent NS5A inhibitor, BMS-790052 that is under evaluation in combination with 
other drugs, and this has stimulated studies targeting proteins with lack of intrinsic enzymatic or 
receptor functionality.
112
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          Figure 145. Enzymatic and non enzymatic drug targets for HCV
112
 
 
 
High throughput HCV screening programs were used to identify potential drug leads, 
various natural products and extracts were tested for their HCV activity. For example, the well 
absorbed celgosivir (Figure 146) is a valuable oral prodrug of the natural product 
castanospermine that inhibits α-glucosidase I, an enzyme that plays an important role in viral 
maturation by initiating the N-linked oligosaccharides of the viral envelope glycoproteins.
113
 
However, most of the agents are not effective as a monotherapy for the treatment of HCV, but 
demonstrated a synergistic effect in combination with the current standard of care pegylated α-
interferon (IFN). The most frequently used treatment involves a weekly injection of a 
combination of (IFN) and ribavirin (Figure 146), which are only 50% effective and have serious 
side effects including depression and influenza-like symptoms in more than 60% of the 
patients.
114
 An herbal medicine (Mao-to) in combination with natural IFN-β was tried for 
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eighteen Japanese patients with chronic HCV characterized by a high serum viral load (1 
meq/mL) and genotype-1b who seem to be resistant to interferon (IFN) therapy. Sixteen of the 
18 patients (89 %) tested negative for serum HCV RNA at the end of treatment, but only two of 
them (11%) remained negative for the viral RNA at the six month of follow-up studies.
115
 
Recently various natural glucosidases inhibitors were reported such as deoxynojirimycin (Figure 
146) and its derivatives.
116
 In addition, a non-immunosuppressive derivative of cyclosporine A, 
NIM811 (Figure 146), was shown to possess anti-HCV activity through binding to 
cyclophilin.
116
 More  recently, Telaprevir and Bocepravir were approved by the FDA, but even 
these potent protease inhibitors are effective at most 80% of the time when combined with 
standard of care (IFN) (Figure 146). 
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    Figure 146. Structures of selected anti-HCV active compounds 
 
 
 Recently, we began to evaluate the anti-HCV properties of rare Latin American plant 
extract provided by Newman of the Natural Products Branch of the National Cancer Institute 
(repository #77951); collected from Ecuador; longitude: 77 055.02 W latitude: 046.98 N) under a 
specific Material Transfer Agreement (MTA) that protects the rights of Ecuador. Diplostephium 
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rhododendroides (family Asteraceae) found in Ecuador and Colombia and it is no surprise that 
this species has not been subjected to any major phytochemical screening. Diplostephium (Figure 
147) is a genus composed of approximately 110 species. Colombia has 63 species and 
Diplostephium is the third most diverse genus on the paramos at the border between Colombia 
and Ecuador.
117
 
 
  Figure 147. Selected species from the genus Diplostephium  
 
The HCV inhibitory guided evaluation of the rhododendroides extract led to the isolation 
and identification of a group of unique and complicated oleanane-triterpene glycosides 
rhododendrosaponins I-III with m/z of 1722-1764. The isolation of the active metabolites was 
challenging due to the limited amount of extract and the absence of additional fresh plant 
material. The extraction started with a rapid solvent elution utilizing MeOH-DCM, where the 
active metabolites were extracted in DCM-MeOH (25:75) (Scheme 9), followed by HPLC on 
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250  21.2 mm C18 column with MeOH-H2O, where the active material eluted off the column as 
a broad signal by the end of the elution (Scheme 10, Figure 148). The material representing this 
broad signal was subjected to 250  21.2 mm NH2 column with CHCl3-MeOH to yield three UV 
inactive metabolites (Scheme 11, Figure 149). The three resolved metabolites were further 
subjected to 250  4.6 mm NH2 (Figure 150), and the co-injection of metabolites 2 and 3 on 250 
 4.6 mm NH2 column was also completed (Figure 151). The complete 1D and 2D NMR data 
sets of rhododendrosaponins I-III were gathered (Figures 152-180). Evaluation of  
1
H and 
13
C 
NMR data of the rhododendrosaponins I-III permitted the validation of the basic skeletons of the 
oleanane-type triterpenes [polygalacic acid; (2β,3β,4α,16α)-2,3,16,23-tetrahydroxyolean-12-en-
28-oic acid] with one characteristic double bond (Figure 181),
 118
 where H-12 (5.34 Hz) shows 
an HMBC correlation to C-14 (40.9 Hz); H-23 shows HMBC correlations to C-3 (84.0 Hz), C-4 
(43.1 Hz), C-5 (48.3 Hz) and C-24 (65.6 Hz);. H-25 (1.22 Hz) shows HMBC correlations to C-1 
(44.4 Hz), C-5 (48.3 Hz), C-9 (48.2 Hz) and C-10 (37.6 Hz); H-26 (0.72 Hz) shows HMBC 
correlations to C-7 (33.8 Hz), C-8 (42.9 Hz), C-9 (48.2 Hz) and C-14 (40.9 Hz);  H-27 (1.31 Hz) 
shows HMBC correlations to C-8 (42.9 Hz), C-13 (144.8 Hz), C-14 (40.9 Hz) and C-15 (36.4 
Hz); H-30 (0.81 Hz) shows HMBC correlations to C-19 (48.2 Hz), C-21 (35.5 Hz) and C-29 
(25.0 Hz). In addition mild hydrolysis using dioxane containing HCl followed by GC/MS 
analysis, showed the presence of 3-hydroxybutanoate (Figure 182). This was confirmed by 
HMBC correlations of the 3-hydroxybutanoate dimer, where H-2′ (2.83 Hz) shows HMBC 
correlations to C-1′ (171.5 Hz), C-3′ (68.8 Hz), and C-4′ (20.8 Hz), while H-2′′ (2.52 Hz) shows 
HMBC correlations to C-1′′ (172.6 Hz), C-3′′ (65.6 Hz), and C-4′′ (23.6 Hz) (Figure183).  
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Scheme 9. Fractionation of Diplostephium rhododendroides extract via solvent extraction,   
blue color indicated the presence of the Rhododendrosaponins I-III  
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Scheme 10. Fractionation of Fr. 3; DCM-MeOH (25:75), on 250 x 21.2 mm C18 column, 
blue color indicated the presence of the rhododendrosaponins I-III  
 
 
 
            Figure 148. HPLC chromatogram of Fr. 3; DCM-MeOH (25:75), on 250 x 21.2 mm 
C18 column  
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Scheme 11. Fractionation of Fr. C; (60-80 min off C18), on 250 x 21.2 mm NH2 column, 
blue color indicated the presence of the rhododendrosaponins I-III 
 
 
          Figure 149. HPLC chromatogram of Fr. C; (60-80 min off C18), on 250 x 21.2 mm NH2 
column, signals 1-3 indicated the presence of the rhododendrosaponins I-III 
in similar order. 
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                  Figure 150. Re-injection of rhododendrosaponins I and II on 250  4.6 mm NH2 column 
 
 
 
 
 
          Figure 151. Co-injection of rhododendrosaponins I and II on 250  4.6 mm NH2 column 
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         Figure 152. (+)-HRESIMS spectrum of rhododendrosaponin I 
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         Figure 153. 1H NMR spectrum of rhododendrosaponin I in methanol-d4 (600 MHz); A) 
the full spectrum, B) the downfield region 
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                Figure 154. 13C NMR spectrum of rhododendrosaponin I in methanol-d4 (600 MHz); A) 
the full spectrum, B) the downfield region 
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               Figure 155. 135º DEPT spectrum of rhododendrosaponin I in methanol-d4 (600 MHz); 
A) the full spectrum, B) the downfield region 
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                   Figure 156. HSQC spectrum of rhododendrosaponin I in methanol-d4 (600 MHz); A) 
the full spectrum, B) the downfield region 
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Figure 157. COSY spectrum of rhododendrosaponin I in methanol-d4 (600 MHz); A)        
the full spectrum, B) the downfield region 
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         Figure 158. HMBC spectrum of rhododendrosaponin I in methanol-d4 (600 MHz); A) 
the full spectrum, B) the downfield region 
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               Figure 159. TOCSY spectrum of rhododendrosaponin I in methanol-d4 (600 MHz); A) 
the full spectrum, B) the downfield region 
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           Figure 160. ROESY spectrum of rhododendrosaponin I in methanol-d4 (600 MHz); A) 
the upfield region, B) the downfield region 
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         Figure 161. (+)-HRESIMS spectrum of rhododendrosaponin II 
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               Figure 162. 
1
H NMR spectrum of rhododendrosaponin II in methanol-d4 (600 MHz) 
 
 
 
 
 
         Figure 163. 
13
C NMR spectrum of rhododendrosaponin II in methanol-d4 (600 MHz) 
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             Figure 164. 135º DEPT spectrum of rhododendrosaponin II in methanol-d4 (600 MHz) 
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                 Figure 165. HSQC spectrum of rhododendrosaponin II in methanol-d4 (600 MHz); A) 
the full spectrum, B) the downfield region 
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                   Figure 166. COSY spectrum of rhododendrosaponin II in methanol-d4 (600 MHz); A) 
the full spectrum, B) the downfield region 
 187 
 
 
 
 
 
 
                Figure 167. HMBC spectrum of rhododendrosaponin II in methanol-d4 (400 MHz); A) 
the full spectrum, B) the upfield region 
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                   Figure 168. H2BC spectrum of rhododendrosaponin II in methanol-d4 (400 MHz); A) 
the full spectrum, B) the downfield region 
 189 
 
 
 
 
 
 
                  Figure 169. TOCSY spectrum of rhododendrosaponin II in methanol-d4 (600 MHz); A) 
the full spectrum, B) the downfield region 
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           Figure 170. NOESY spectrum of rhododendrosaponin II in methanol-d4 (600 MHz); 
A) the full spectrum, B) the downfield region 
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         Figure 171. LC/MS chromatogram of rhododendrosaponin III 
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           Figure 172. 
1
H NMR spectrum of rhododendrosaponin III in methanol-d4 (600 MHz); 
A) the full spectrum, B) the downfield region 
 193 
 
 
 
 
 
 
           Figure 173. 13C NMR spectrum of rhododendrosaponin III in methanol-d4 (600 MHz); 
A) the full spectrum, B) the downfield region 
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           Figure 174. 135º DEPT
 
spectrum of rhododendrosaponin III in methanol-d4 (600 
MHz); A) the full spectrum, B) the downfield region 
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                  Figure 175. HSQC spectrum of rhododendrosaponin III in methanol-d4 (600 MHz); A) 
the full spectrum, B) the downfield region 
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                  Figure 176. HMBC spectrum of rhododendrosaponin III in methanol-d4 (400 MHz); A) 
the full spectrum, B) the upfield region 
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         Figure 177. COSY spectrum of rhododendrosaponin III in methanol-d4 (400 MHz) 
 
 
 
 
 
          Figure 178. H2BC spectrum of rhododendrosaponin III in methanol-d4 (600 MHz) 
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                  Figure 179. TOCSY spectrum of rhododendrosaponin III in methanol-d4 (600 MHz); 
A) the full spectrum, B) the downfield region 
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               Figure 180. NOESY spectrum of rhododendrosaponin III in methanol-d4 (600 MHz) 
A) the full spectrum, B) the integrated NOESY 
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         Figure 181. Selected HMBC correlations of the aglycone triterpene 
 
 
 
 
           Figure 182. GC/MS detection of 3-hydroxybutanoate in rhododendrosaponin III 
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         Figure 182. HMBC correlations of 3-hydroxybutanoate dimmer in 
rhododendrosaponin III 
 
Rhododendrosaponins II and III were shown by (+)-HRESIMS to possess similar masses 
at m/z 1722.6523-1722.6498 for the sodiated species, [C78H124O40+Na]
+
, calcd 1722.7488 
Figures 161 and 171, while rhododendrosaponin I shows a mass at m/z 1764.7908 for the 
sodiated species [C80H126O41+Na]
+
, calcd 1764.7594 Figure 152 and the presence of an extra 
acetyl group attached at C-23 was confirmed by stacked plot the proton and carbon spectra of 
rhododendrosaponins I-III as well as ROESY spectrum of rhododendrosaponin I (Figures 183, 
184, and 160).  
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             Figure 183. Stacked plot the 1H NMR spectra of rhododendrosaponins I-III 
 
 
 
 
 
         Figure 184. Stacked plot the 13C NMR spectra of rhododendrosaponins I-III 
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 Identification and determination of the carbohydrate units were established using 
13
C 
NMR and GC/MS/MS data while the determination of the sequence of oligosaccharides was 
completed through detailed MS studies including fragmentation by Nanospray Ionization-Linear 
Ion Trap Mass Spectrometry (NSI-MS
n
) through collaboration with the Complex Carbohydrate 
Research Center at The University of Georgia.
 
The total carbohydrate content of the major 
glycoside rhododendrosaponin III was shown by GC analysis to be 73.8% by weight. The 
processed data revealed the presence of a glucosyl, two arbinosyl, a rhamnosyl, a fucosyl, and 
two xylosyl units (Table 14). Inositol was added to the sample before derivatization as an 
internal standard (20 µg/sample) and the monosaccharides are identified by their retention times 
in comparison to standards and the carbohydrate character of these are authenticated by their 
mass spectra. 
 
           Table 14. Monosaccharide analysis of rhododendrosaponin III by GC/MS 
Residue Weight (ug)
1
 mole% 
Arabinose(Ara) 77.2 27.5 
Ribose(Rib) n.d. n.d. 
Rhamnose (Rha) 48.4 15.8 
Fucose (Fuc) 43.7 14.2 
Xylose (Xyl) 86.7 30.9 
Glucuronic acid(GlcUA) n.d. n.d. 
Galacturonic acid (GalUA) n.d. n.d. 
Mannose (Man) n.d. n.d. 
Galactose (Gal) n.d. n.d. 
Glucose (Glc) 39.2 11.6 
N-Acetylgalactosamine (GalNAc) n.d. n.d. 
N-Acetyl-glucosamine (GlcNAc) n.d. n.d. 
Heptose(Hep) n.d. n.d. 
3-Deoxy-2-manno-2-octulsonic acid (KDO) n.d. n.d. 
Sum  100 
1
Values are expressed as mole percent of total carbohydrate, n.d. = none detected. Values 
under 2 ug are given as rough estimates only due to poor linearity of the assay in these 
regions. 
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 The glycosyl linkages were summarized in (Table 15). The determination of the sequence 
of oligosaccharides was done via full MS and fragmentation by (NSI-MS
n
) (Figure 185). 
Table 15. Glycosyl linkage analysis for rhododendrosaponin III  
Glycosyl Residue Percentage Present 
Terminally linked arabinofuranosyl residue (t-Araf) 2.6 
Terminally linked arabinopyranosyl residue (t-Arap) 21.9 
Terminally linked xylopyranosyl residue (t-Xylp) 9.2 
4-linked rhamnopyranosyl residue (4-Rhap) 19.7 
Terminally linked glucopyranosyl residue (t-Glcp) 2.2 
2-linked fucopyranosyl residue (2-Fucp) 1.9 
3-linked xylopyranosyl residue (3-Xylp) 12.0 
2,3-linked fucopyranosyl residue (2,3-Fucp) 16.3 
6-linked glucopyranosyl residue (6-Glcp) 8.8 
4-linked glucopyranosyl residue (4-Glcp) 0.7 
2,6-linked glucopyranosyl residue (2,6-Glcp) 4.7 
Total 100 
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        Figure 185. NSI-MS
n
 fragmentation of rhododendrosaponin III  
 
 
 The absolute configuration determination of the carbohydrate units was completed using 
an HPLC method reported by Tanaka et al.
119
 First the compound is hydrolyzed via refluxing in 
1 N HCl for 2-3 h followed by extraction with ethyl acetate. The aqueous layer is then 
neutralized with silver carbonate, centrifuged to remove the insoluble precipitate, dried, refluxed 
with L-cysteine methyl ester in pyridine for 1 hr at 60-70 °C, followed by the addition of 
phenylisothiocyanate with extended reflux for an additional 1 hr at 60-70 °C to form the 
thiazoline derivative that can be detected by UV (Scheme 12). This method was tested using 
various standards (Figures 186, 187 and Table 16), followed by application to the isolated 
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metabolites (Figures 188, 190, and 191). The gross structure of the major metabolite 
rhododendrosaponin III was shown in Figure 189. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Scheme 12. An investigational method for carbohydrate analysis
101 
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          Figure 186. L- and D-glucose standards by carbohydrate analysis method 
 
 
 
           Figure 187. L- and D- glucose, xylose, and fucose standards by the carbohydrate 
analysis method 
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         Table 16. The retention times of the carbohydrate standards 
Carbohydrate RT 
D-Arabinose 18.77 
L-Arabinose 18.41 
D-Glucose 18.07 
L-Glucose 17.81 
D-Xylose 18.79 
L-Xylose 18.61 
D-Fucose 19.42 
L-Fucose 20.05 
L-Rhamnose 17.10 
 
 
 
 
          Figure 188. Carbohydrate analysis for rhododendrosaponin III 
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    Figure 189. The gross structure of rhododendrosaponin III 
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          Figure 190. Overlay of the carbohydrate analysis chromatograms of 
rhododendrosaponins I and III 
 
 
                 Figure 191. Carbohydrate analysis chromatogram of rhododendrosaponin II 
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Overlaying the most common 2D NMR experiments including 
1
H-
13
C) Heteronuclear 
Multiple Quantum Coherence Spectroscopy (HSQC), 
1
H-
13
C (2 and 3 bond) Heteronuclear 
Single bond Correlation Spectroscopy (HMBC) and 
1
H -
1
H Nuclear Overhauser Enhancement 
spectroscopy (NOESY/ROESY) helped to alleviate the extended time to quickly solve such 
considerably complex homologous series. Overlaid HSQC data for rhododendrosaponins I and 
III revealed a high level of homology (Figure 192) with interchangeable α- and β- configuration 
at C-24 of rhododendrosaponins I. This was confirmed with the HSQC, HMBC, and ROESY 
spectra of rhododendrosaponins I shown in Figures 193, 194, and 195. Interestingly, the 
superimposed data clearly demonstrated the presence of the uncommon Amadori-type pyranose-
furanose isomerism of the terminal L-arbinosyl moiety. It was possible to monitor the presence of 
acyclic intermediate (-CHO) at 218.1 ppm (Figure196). As further evidence, the glycosyl linkage 
analysis (Table 15) confirmed the presence of both forms. These data explains the complex 
NMR spectra for these compounds. 
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          Figure 192. Overlaid HSQC spectra of rhododendrosaponins I and III 
 
 
 
 
 
          Figure 193. The expanded HSQC spectrum of rhododendrosaponin I in methanol-d4 
(600 MHz) shows the presence of α and β isomers at C-24  
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 Figure 194. The expanded HMBC spectrum of rhododendrosaponin I in methanol-d4 
(600 MHz) shows the presence of α and β isomers at C-24 
 
 
 
 Figure 195. The expanded ROESY spectrum of rhododendrosaponin I in methanol-d4 
(600 MHz) shows the presence of α and β isomers at C-24 
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 Figure 196. 135º DEPT spectrum of rhododendrosaponin I in methanol-d4 (600 MHz) 
shows the presence of (-CHO) for the acyclic intermediate  
 
 
 
 
In a similar manner stacked HSQC studies for rhododendrosaponins II and III revealed 
high level of similarity (Figure 197) with pyranose-furanose isomerism. This was confirmed by 
monitoring the presence of the acyclic intermediate (-CHO) at 217.590 ppm (Figure 198), as well 
as the presence of arbinofuranosyl unit in rhododendrosaponin II (Figure 199). Further 
investigation through co-injection of rhododendrosaponins II and III on 250  21.2 mm NH2 
column with CHCl3-MeOH confirms the isomerization (Figure 200) which may be catalyzed by 
the NH2 stationary phase (Figure 201).  
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         Figure 197. Overlaid HSQC spectra of rhododendrosaponins II and III 
 
 
 
 
 Figure 198. The 
13
C NMR spectrum of rhododendrosaponin II in methanol-d4 (600 
MHz) shows the presence of (-CHO) for the acyclic intermediate 
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  Figure 199. Expanded HMBC spectrum of rhododendrosaponin II in methanol-d4 
(600 MHz) shows the presence of arbinofuranosyl moiety 
 
 
 
 
                       Figure 200. Co-injection of rhododendrosaponins II and III on 250  4.6 mm NH2 column 
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                          Figure 201. 135º DEPT spectrum of active fraction after 250 x 21.2 mm C18 and 
rhododendrosaponin I after 250 x 21.2 mm NH2 in methanol-d4 (600 
MHz) 
 
1
H NMR data for rhododendrosaponins I established the β-configuration of the following 
glycosyl groups: fucosyl (5.42 d, 7.8 Hz), glucosyl (4.57, 7.8 Hz), terminal xylosyl (4.24 d, 6.0 
Hz), inner xylosyl (4.52 d, 6.0 Hz), terminal arabinosyl (4.48 d, 7.8 Hz), and inner arabinosyl 
(4.54 d, 6.6 Hz), while α-configuration of rhamnosyl (5.35, s). The 3β absolute configuration of 
3-hydroxybutanoate was determined by acid-catalyzed methanolysis. This was followed by 
comparison with (R) and (S) standards using a chiral GC column [RESTEK capillary column: 
St-βDEXsa (30 m x 0.32 mm x 0.25 µm)], Figures 202 and 203. 
The proposed structures of the three isolated metabolites are shown in Figure 204. The 
3D structure of the major glycoside, rhododendrosaponins III was minimized using OPLS_2005 
with extended cutoff; Van der Waals of 8.0 K cal/mol, Electrostatic of 20.0 K cal/mol, and H-
bond of 4.0 K cal/mol. All stereogenic centers are kept fixed during the calculation. PRCG 
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method was used with 0.05 as a convergence gradient threshold. Mixed torsional/low-mode 
sampling was used for conformational analysis with 1000 number of steps. PyMol 1.4 was used 
to generate the 3D surface with element color scheme as shown in Figure 205. Despite the 
presence of similarity to previously reported natural products, the rarity of the source, the 
exceptional activity, and the presence of the uncommon Amadori-type isomerism make this 
group of metabolites unique.
118,120
 
 
 
 
 
 
          Figure 202. GC chromatograms of: A) (R)-methyl 3-hydroxybutanoate, B) (S)-methyl 
3-hydroxybutanoate, C) Co-injection of (R) and (S)-methyl 3-
hydroxybutanoate  
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Figure 203. GC chromatograms of: A) rhododendrosaponins I-III after methanolysis, 
B) Co-injection of the sample and (R)-methyl 3-hydroxybutanoate, C) 
Co-injection of the sample and (S)-methyl 3-hydroxybutanoate  
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    Figure 204. The proposed structures of rhododendrosaponins I-III 
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 Figure 205. The minimized 3D structure surface generated by PyMol 1.4 for 
the major glycoside, rhododendrosaponin III, red represents 
oxygen while green and grey represent carbon and hydrogen.  
. 
 
 
Rhododendrosaponins I-III were evaluated at six different concentrations for anti-HCV 
activity and end point determination in Huh-7 replicon Cells (Table 17). Huh-7 B cells 
containing HCV genotype 1 replicon RNA were seeded in a 96-well plate at 3,000 cells/well and 
the compounds were added in dose response at 10, 3, 1, 0.3, 0.1, and 0.03 µg/mL in triplicate 
immediately after seeding. Following five days incubation (37 °C, 5% CO2), total cellular RNA 
was isolated using the Manual Perfect Pure RNA 96 Cell Vac kit from 5 prime. Replicon RNA 
and an internal Control (TaqMan rRNA control reagent, Applied Biosystems) were amplified in 
a single step multiple Real Time RT-PCR assay.  
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Table 17. Anti-HCV activity of rhododendrosaponins I-III in Huh-7 replicon cells  
 
Sample Code 
 
Concentration 
µg/mL 
 
 
ΔCt  
HCV 
 
 
ΔCt 
rRNA 
 
% Inhibition 
 
 
EC50 
µg/mL 
 
EC90 
µg/mL 
 
CC50 
µg/mL HCV rRNA 
 
RS-446 0.3 
0.8 
2.6 
0.49 
1.53 
4.28 
0.01 
-0.57 
-0.63 
28.89 
65.18 
94.79 
0.69 
-47.93 
-54.19 
0.6 2.3 >2.6 
Rhododendrosaponin I 0.03 
0.1 
0.3 
1.0 
3.0 
10.0 
-0.66 
-0.22 
2.60 
5.35 
7.08 
7.04 
-1.10 
-0.89 
-0.44 
-0.85 
-0.21 
6.04 
-57.78 
-16.69 
83.37 
97.51 
99.25 
99.23 
-113.35 
-85.39 
-35.22 
-79.51 
-15.35 
98.46 
0.2 0.6 7.0 
Rhododendrosaponin II 0.03 
0.1 
0.3 
1.0 
3.0 
10.0 
-0.07 
-0.08 
1.84 
3.67 
7.44 
7.07 
-0.23 
-0.99 
-1.18 
-0.97 
0.15 
1.96 
-5.20 
-5.68 
71.89 
92.10 
99.41 
99.24 
-16.96 
-98.19 
-126.52 
-95.02 
10.05 
74.16 
0.2 0.9 7.4 
Rhododendrosaponin III 0.03 
0.1 
0.3 
1.0 
3.0 
10.0 
-0.63 
-0.42 
3.95 
5.36 
6.88 
7.50 
-1.81 
-0.98 
0.59 
-0.75 
0.44 
6.27 
-54.19 
-33.67 
93.49 
97.53 
99.14 
99.44 
-249.27 
-96.38 
33.40 
-67.91 
26.05 
98.69 
0.2 0.3 5.3 
 
The antiviral effectiveness of the compounds was calculated by subtracting the threshold 
RT-PCR cycle of the test compound from the threshold RT-PCR cycle of the non-drug control 
(ΔCtHCV). A ΔCt of 3.3 equals a 1-log reduction (equal to 90% less starting material) in 
replicon RNA levels. The cytotoxicity of the compounds was also calculated by using the ΔCt 
rRNA values. RS-446 (2′-C-Me-C) Figure 146, was used as the control. To determine EC50 and 
IC50 values, ΔCt values were first converted into fractions of starting material and then were used 
to calculate the percent inhibition.
121
 The activity profile clearly revealed significant potency for 
these metabolites comparable to the recently approved drug Telaprevir (EC50 0.1-0.2 µg/mL)
122
 
and a therapeutic window warranted to inspire further investigations. 
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STUCTURE ELUCIDATION OF HETERONEMIN FROM THE NCI (repository No. 207161), 
HYRTIOS RETICULATA 
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       Figure 206. 1H NMR spectrum of heteronemin in CDCl3 (400 MHz) 
 
 
 
 
 
       Figure 207. 13C NMR spectrum of heteronemin in CDCl3 (400 MHz) 
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        Figure 208. 135º DEPT spectrum of heteronemin in CDCl3 (400 MHz) 
 
 
 
 
 
        Figure 209. HMBC spectrum of heteronemin in CDCl3 (400 MHz) 
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